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ABSTRACT 
CD56-SPECIFIC T CELLS: USING GENETICALLY ENGINEERED T CELLS TO 
REDIRECT SPECIFICITY TO A T CELL EXPRESSED ANTIGEN 
  
Denise Louise Crossland, B.S. 
 
Advisory Professor: Laurence Cooper, MD, Ph.D. 
 
The CD56 antigen is expressed on several deadly malignancies 
currently lacking long-term efficacious therapies. Chimeric 
antigen receptor (CAR) based immunotherapies have shown both 
safety and efficacy and even a curative ability in clinical 
trials, laying the foundation for applying CARs to new 
targets. Using T cells to target a T cell expressed antigen, 
such as CD56, seems counterintuitive in that the T cells would 
be susceptible to self-targeting a.k.a. fratricide. However, 
we expand CD56-specific CAR+ T cells that co-express the CD56 
antigen. Since other CARs targeting T cell expressed antigens 
are hypothesized to be undergoing fratricide, such as the 
CD38-specific CAR, this unexpected observation of CD56+CD56CAR+ 
T cells infers that these cells are unique in their survival 
capacity in a self-targeting scenario. CD56CAR+ T cells have 
redirected specificity to CD56+ tumor cells and generate anti-
tumor responses in neuroblastoma xenograft studies in mice. 
These CD56CAR+ T cells expand similarly to CAR+ T cells that do 
not target self-antigen, CD19-specific CAR+ T cells, and do not 
undergo fratricide. The CD56 antigen co-expressed by CD56CAR+ T 
cells has diminished ability to stain with the CD56 monoclonal 
antibody clone N901, which is the epitope where the CAR binds, 
while the CD56 antigen on CD19CAR+ T cells retains staining. 
Our data strongly suggest that this epitope loss is not a 
result of epitope escape of the CD56 antigen. Significant 
differences in the protein expression profiles of CD19CAR+ and 
CD56CAR+ T cells, which may be responsible for fratricide 
evasion of CD56+CD56CAR+ T cells, were observed. Further 
investigation into these protein differences could delineate a 
key pathway or responsible for fratricide evasion and be 
applied in the generation of other CAR based immunotherapies 
targeting T cell expressed tumor associated antigens. 
Targeting T cell expressed antigens not only has implications 
for cancer therapies, but also for treating autoimmune 
diseases, for the manipulation of transplants or to ablate 
existing immune cells in a patient as an alternative to 
chemotherapy. 
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CHAPTER 1: BACKGROUND 
1.1 Chimeric antigen receptor based adoptive immunotherapy 
Since tumors have several mechanisms by which they evade 
immune detection including reducing major histocompatability 
complex (MHC) expression, lacking co-stimulatory molecules 
necessary for T cell activation and defective antigen 
processing, T cells require modifications to allow tumor 
recognition despite the tumors evasion [1,2,3,4,5]. A form of 
therapy where the cells are taken from either the patient 
themselves (autologous) or a matched donor (allogenic) and ex 
vivo expanded to be used as a therapy is called adoptive cell 
transfer (ACT)[5,6]. One form of ACT is to genetically modify 
the T cells to target the cancer based upon a tumor specific 
cell surface antigen [1,3,5,7,8]. To achieve this end our lab 
transduces peripheral blood mononuclear cells (PBMCs) using 
the Sleeping Beauty (SB) system of transfection, a 
transposons/transposase system of gene transfer that functions 
through a cut and paste mechanism [3,9,10,11], to express a 
chimeric antigen receptor (CAR). CARs combine the specificity 
region of a mAb, the single chain variable fragment (scFv), 
and some of the signaling domains responsible for T cell 
activation. Originally the CD3 zeta (ζ) endodomain alone was 
used for downstream CAR signaling, this is called the first 
generation CAR. More recently the second generation CAR was 
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designed where the CD3ζ endodomain has been fused to the CD28 
transmembrane and endodomain to achieve costimulatory 
signaling necessary for enhanced T cell activation, survival, 
and effector function [1,2,3,4,7,8,10,12,13,14,15,16]. Studies 
are currently moving into more advanced forms of CARs, the 
third generation CAR, where additional endodomains of 
costimulatory molecules (4-1BB, OX-40L, etc.) have been fused 
to the intracellular portion for enhanced CAR function 
[2,3,4,7,8,12,13,14,15,16]. 
 The advantages of CAR based immunotherapies include (i) 
antigen specificity independent of MHC which allows 
application of one CAR to all patients, (ii) potential 
systemic therapy since T cells are capable of trafficking 
throughout the body and tumors, and (iii) potential for 
longevity of the therapy since T cells have the capacity to 
produce memory [1,3,7,8]. CAR based immunotherapies have been 
tested in several clinical trials for multiple cancer targets 
including CD19, CD20, GD2 and L1-CAM[2,3,4,8,16]. Even though 
CAR technology has been available and studied for over a 
decade, the actual downstream signaling achieved through the 
CAR as compared to that achieved through natural T cell 
receptor has not been investigated leaving a gap in our 
understanding of how CAR-based therapies function. 
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1.2 Redirecting T-Cell specificity to T Cell expressed 
antigens 
Some candidate tumor associated antigens (TAAs) are also 
expressed on T cells, limiting the use of T cells to target 
such molecules. These TAAs include CD30 which is expressed on 
Hodgkin’s lymphoma [17] , CD38 which is expressed on B-cell 
non-Hodgkin lymphoma [18], CD44v6 which is expressed on acute 
myeloid leukemia (AML) and multiple myeloma (MM)[19] and CD56 
which is expressed on many aggressive malignancies [20] as 
discussed in “CD56 and cancer”. Other groups have begun to 
investigate the ability to redirect T cell specificity to CD30 
CD38, and CD44v6 using CARs [18,19,21] despite the capacity for 
self-targeting, fratricide, since T cells are capable of 
killing T cells [22]. Salvodo et al generated a CD30-specific 
CAR (CD30CAR) and noted only small percentages (<10%) of their 
activated T cells expressing CD30. Their assessment of 
fratricide mediated by expression of the CD30CAR has not been 
investigated in depth, although the CD30CAR+ T cells are 
demonstrated to be functional [21]. Cassuci et al. did not 
discuss experiments assessing the ability of CD44v6-specific 
CAR+ T cells to perform fratricide but do mention low level 
expression on normal activated T cells [19]. Mihara et al 
generated a CD38-specific CAR (CD38CAR) and propose that their 
cells are undergoing autolysis since they could not expand out 
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CD38CAR+ T cells unless cultured in the presence of CD38 
antibodies [18]. Although CD38CAR+ T cells are functional, the 
capacity to target themselves when not in the presence of CD38 
antibodies could impact the in vivo survival and functional 
capacity of these cells. 
 In addressing the generation of a CD56-specific CAR 
(CD56CAR) we determined the percent CD56+ T cells expanding 
under our culture conditions with the CD19-specific CAR 
(CD19CAR) to determine what effect the loss of this CD56+ 
population of CAR+ T cells could have on culture kinetics. Over 
the 28 day co-culture period CD19CAR+ T cells contained up to 
60% CD56+ T cells depending upon donor. We decided to proceed 
forward with the generation and expression of the CD56CAR in T 
cells to determine if we could indeed redirect T cell 
specificity to CD56 and simultaneously followed CD56 
expression. To our surprise CD56CAR+ T cells were co-expressing 
CD56 and expanding in the culture. Since other CARs targeting 
T cell expressed antigens are hypothesized to be undergoing 
autolysis, such as the CD38-specific CAR, this unexpected 
observation of CD56+CD56CAR+ T cells infers that these cells 
are unique in their survival capacity in a self-targeting 
scenario. Understanding how these CD56+CD56CAR+ T cells survive 
can potentially improve upon the ability to generate T cells 
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capable of targeting T cell expressed TAAs without targeting 
themselves. 
1.3 CD56 a.k.a. Neural Cell Adhesion Molecule (NCAM) 
Neural cell adhesion molecule has been extensively studied 
for its role in synaptic plasticity and neuronal development 
[23,24,25,26]. NCAM is a surface molecule known to have many 
functions beyond cell-cell adhesion through homophilic 
binding, such as signaling capacities through activation of 
intracellular signaling pathways, formation of signaling 
complexes [23,24,25,26,27,28], impacting cytoskeletal 
dynamics[25,27,28], as well as activating growth factor 
signaling pathways[24,28]. This multifunctional adhesion 
molecule is a member of the immunoglobulin superfamily and is 
expressed as several isoforms dependent on posttranscriptional 
alternative splicing of the single gene located on chromosome 
11. All of the isoforms contain an extracellular domain 
consisting of five immunoglobulin-like (Ig) modules and two 
fibronectin type III (F3) modules[23,24,25,26,27,28]. This 
extracellular domain has a wide range of binding partners 
including both homophilic and heterophilic ligands of which 
the exact mechanisms of binding are still controversial, 
though many theories exist including cis and trans 
binding[26,27,28,29] forming either “compact” or “flat” 
zippers[24,27,28,29]. A unique characteristic of NCAM, which 
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is thought to impact its binding capacity, is the ability to 
carry the negatively charged sugar, polysialic acid (PSA), 
attached post-translationally to the fifth Ig module. PSA 
expression decreases during development and is hypothesized to 
play a role in altering NCAM function from a plasticity-
promoting molecule to a stability-promoting molecule 
[23,24,25,26,28]. Studies of NCAM knockout mice demonstrate 
minor brain abnormalities but overall are viable, healthy, and 
fertile [24,26]. Some of these abnormalities such as deficits 
in spatial learning correlate with studies demonstrating 
increased NCAM synthesis after learning tasks[23]. These mice 
also have decreased size of the olfactory bulb, and defects in 
fasciculation and path finding of hippocampal mossy fibers 
[24,26]. 
NCAM has six highly conserved sites for N-linked 
glycosylation (N1-N6) with N1 being on Ig3, N2 and N3 on Ig4 
and N4-N6 on Ig5. Only N5-N6 have the ability to be 
glycosylated with PSA. The protein NCAM also has three 
optionally expressed portions including (1) the variable 
alternative splice exon (VASE), which is only 10 amino acids 
(aa) long and is expressed within Ig4, (2) the muscle-specific 
domain 1 (MSD1) which is comprised of three regions, MSD1a, -
b, and –c, which are 15, 48 and 42 aa long respectively, and 
(3) the AAG insert which is only one aa long. Both MSD1 and 
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the AAG insert, when expressed, are located in-between FnIII1 
and FnIII2 and MSD1 has the ability to carry O-linked 
glycosylation [30]. 
 The difference between the three main isoforms, NCAM-120, 
NCAM-140 and NCAM-180, is in the intracellular domain. NCAM-
120, 120kDa in size, is expressed only in glia and only 
consists of the extracellular domain linked to the membrane by 
a glycosylphosphatidylinositol (GPI) anchor. NCAM-180, 180kDa 
in size, is expressed only in neurons while NCAM-140, 140 kDa 
in size, is expressed in both neurons and glia. Both NCAM-180 
and NCAM-140 consist of a transmembrane and intracellular 
domain but differ in the length of the intracellular domain 
[23,24,25,26,27,28]. Although first studied in the context of 
neurons, NCAM-140 was demonstrated to be equivalent to an NK 
cell associated antigen referred to as Leu-19, NKH-1, or CD56, 
which is also expressed on a subset of T cells[31]. Despite 
this intriguing discovery the role of CD56 in T cells is yet 
to be elucidated.  
1.3.1 NCAM in neurons 
The ability of NCAM to regulate neuronal plasticity and 
neuroprotection without any known intrinsic enzymatic activity 
or the presence of known motifs for interactions with 
signaling molecules has made NCAM signaling a widely studied 
process. Even with decades of investigation using multiple 
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mechanisms of stimulation including using a co-culture system 
with NCAM expressing fibroblast monolayers, recombinant 
proteins, crosslinking antibodies or peptide specific mimetics 
[24,25,27], many aspects of NCAM signaling in neurons remain 
unclear. Since NCAM signaling in T cells in not known, NCAM 
signaling in neurons will be discussed as a foundation for 
signaling mechanisms that will be studied in this proposal as 
possible routes for signaling of NCAM in T cells.  
 NCAM surface expression has been found to be regulated by 
endocytosis through a clathrin dependent pathway [32] and 
signaling to be achieved through two mechanisms [23,24,25,27]. 
The first mechanism of NCAM mediated downstream signaling is 
through NCAM stimulated formation of signaling complexes 
involving Fyn (a non-receptor tyrosine kinase) and FAK  (focal 
adhesion kinase) interactions, while the second downstream 
signaling mechanism is through NCAM mediated activation of a 
tyrosine kinase receptor, the fibroblast growth factor 
receptor (FGFR)[23,24,25,26,27,28,29], by transphosphorylation 
[25,27,28]. Signaling cascades resulting from downstream 
activation of these pathways show evidence of convergence 
[24,25,28] and it is hypothesized that redundancy of these 
pathways is necessary for reaching the amplitude of overall 
signals necessary for neurite outgrowth [24]. One downstream 
signaling molecule involved in NCAM mediated signaling is 
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calcium [23,24,25,27,28,33]. The intracellular Ca2+ 
concentration has been demonstrated to be increased due to 
influx from voltage-gated Ca2+ channels, non-selective cation 
channels, and intracellular stores [24,27,33]. This Ca2+ influx 
was found to be mediated by both Src-family kinases (most 
likely through Fyn) and FGFR induction of the phospholipase C 
pathway (PLC-γ) [24,27,28,33]. Aside the increase in Ca2+ 
influx, the Fyn/FAK and FGFR mediated pathways converge at the 
activation of the mitogen activated protein kinase (MAPK) 
pathway through phosphorylation of  extracellular signal 
related kinase 1 (ERK1) and ERK2 [24,27,28], as well as at the 
activation of protein kinase C (PKC). Other molecules found to 
be activated downstream of NCAM stimulation, most likely 
through FGFR signaling but potentially through Fyn/FAK, 
include protein kinase A (PKA), calcium calmodulin-dependent 
protein kinase II (CaMKII), and phosphatidylinositol 3-kinase 
(PI3K) which in turn activate Akt by phosphorylation. Some 
transcription factors (TF) activated through NCAM signaling 
include cAMP response element binding protein (CREB) most 
likely activated through the MAPK pathway as well as c-Fos and 
NF-kB [23,24,25,27,28]. C-Fos contains the cAMP response 
element and is therefore regulated downstream of CREB and the 
evidence supports NF-kB activation through the PLC, PKC, and 
CaMKII signaling [24,25,27,28]. 
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 Most studies elucidating the molecules downstream of NCAM 
stimulation required for neurite growth and survival were 
based upon inhibition of specific pathways and correlating 
rescue experiments. The wide range of assays and cell lines 
used to develop these signaling pathways is a caveat to 
linking the data received from one study to another [23,24]. 
Even though signaling molecules associated with and required 
for NCAM mediated signaling have been identified a complete 
understanding of these pathways, how they are activated, and 
how they mediate downstream signaling still requires further 
investigation.  
1.3.2 NCAM Signaling in T Cells 
Early studies demonstrated that the NK cell marker 
referred to as CD56, Leu-19, or NKH-1 was actually an isoform 
of NCAM [31]. This 140kDa isoform of NCAM, commonly referred 
to as CD56 when in lymphocytes, was not limited to NK cells 
but was found to be expressed by a subset of T cells 
[31,34,35]. Upon further investigation, this CD56+ subset of T 
cells was associated with MHC unrestricted cytotoxicity 
against NK sensitive targets as well as with a granular 
phenotype indicating the presence of effector proteins 
[34,35]. More recent studies continue to investigate CD56+ T 
cells. In almost all studies CD56+ T cells show MHC 
unrestricted cytotoxicity and CD56 expression has been 
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correlated not only with effector function [36,37,38] but also 
with oligoclonality of the TCR [37,38,39], senescence [37,39], 
resistance to apoptosis [39] and increased expression with 
aging [39,40,41]. From a normal healthy donor CD56+ T cells are 
present in the peripheral blood at low percentages (<5%) 
[35,36,42,43] but show increased numbers in the liver [37,43], 
intestinal tract [42], and bone marrow [37] as well as in 
autoimmune diseases. A study specifically performed on CD56+ T 
cells from inflammatory lesions in rheumatoid arthritis (RA) 
patients demonstrated that ligation of CD56 resulted in the 
production of cytokines such as IL-2, TNF-α, and MIP-1β and 
that production was enhanced upon co-ligation of CD3 and CD56 
simultaneously [44]. Another study more extensively studied 
the capacity of CD56 to act as a modulator of downstream 
signaling upon ligation using the Jurkat T cell line. These 
data demonstrated unique patterns of protein phosphorylation 
compared to that achieved through CD3 ligation using phospho-
serine/threonine and phospho-tyrosine western blots as well as 
phospho-tyrosine flow analysis. The activation of NF-kB, 
increased amounts of the active form of Bcl-2, and loss of Bax 
were all shown using CD56 ligation as well as the ability to 
produce several cytokines including IFN-γ, MIP-1β, TNF-α, and 
IL-8 [39]. Several studies of CD56 on T cell have come from 
groups who generate what are termed cytokine induced killer 
cells (CIKs) for use as a cancer therapy. As a result of the 
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culture environment most of the T cells generated are CD56+ 
[45,46,47]. When phenotypically and functionally characterized 
these cells were concluded to be terminally differentiated 
effector memory T cells [48], with limited proliferative 
capacity, as well as MHC unrestricted cytotoxicity [47,48]. So 
although CD56+ T cells have been found in various scenarios, 
the studies on these T cells and the role of CD56 as a 
functional ligand has been minimally studied and has left a 
huge gap in the basic knowledge of the role CD56 upregulation 
plays in T cells. 
1.3.3 NCAM and cancer 
Several cancers have been found to express NCAM. Some 
have 100% expression including neuroblastoma, 
rhabdomyosarkoma, small cell lung cancer, and brain tumors, 
while others express NCAM at varying percentages such as 
multiple myeloma with 78% expression and acute myeloid myeloma 
with 53% expression [20]. Although extremely controversial, it 
is hypothesized that PSA levels on NCAM can impact the 
prognosis of the cancer. PSA-NCAM is correlated with cell-cell 
adhesion and motility, while having diminished intracellular 
signaling and is thought to correlate with more aggressive and 
malignant cancers with the capacity to metastasize. This 
correlation of aggressiveness of the tumor with high PSA-NCAM 
has been demonstrated for several cancers such as 
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neuroblastoma, several neuroendocrine tumors, and small cell 
lung cancer [20,49,50,51], but is not always the case [50]. 
Low PSA levels are associated with less aggressive and less 
malignant cancers which have an overall better prognosis 
[20,49,50,51]. Despite expression of NCAM on normal healthy 
tissues as well as tumors, several have investigated NCAM as a 
therapeutic target using antibody based therapies [20]. 
Studies using toxin conjugated NCAM-specific mAbs have shown 
safety in phase I trials and some efficacy in phase II trials 
[20,52], while CD3/CD56 bispecific antibodies used in a pilot 
study also showed a clinical response in 8 out of  the 10 
patients [20,53]. These previous trials demonstrate the 
ability to target NCAM in cancer and the potential NCAM based 
therapies have in clinical trials, however, these therapies 
are limited to loco-regional treatments and systemic 
treatments are crucial to minimize relapse. 
1.4 T Cell activation 
T cell activation through ligation of the T cell receptor 
(TCR) will alone activate immediate downstream phosphorylation 
events which lead to the activation of downstream signaling 
cascades ultimately activating transcriptional activity which 
results in activation of genes that give the T cell signals 
for survival, function, and proliferation [54,55]. Initially 
activated upon TCR ligation are the Src protein tyrosine 
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kinases, Lck and Fyn, which in turn phosphorylate the 
immunotyrosine-based activation motifs (ITAMs) of CD3 
[54,55,56]. CD3 phosphorylation recruits ZAP-70 which in 
return activates the adaptor proteins, LAT (linker for the 
activation of T cells) and SLP-76 (Src homology 2 domain (SH2) 
containing leukocyte phosphoprotein of 76 kDa), which act as 
the backbone of signaling complexes capable of activating 
multiple signaling pathways. Activated LAT binds the SH2 
domain of PLC-γ1, the p85 subunit of PI3K, and the growth 
factor receptor-bound protein 2 (Grb2) [54,55]. Activated PLC-
γ1 hydrolyzes PIP2 (phospholipid phosphatidylinositol 4,5 
bisphosphate) generating IP3 (inositol triphosphate) and DAG 
(diacylglycerol). The IP3 results in Ca2+ influx from 
endoplasmic reticulum (ER) stores through activation of the 
Ca2+ permeable ion channel receptors (IP3R) which ultimately 
induces extracellular Ca2+ influx [54,55,56]. The production of 
DAG activates the Ras pathway which acts through the MAPK 
cascade, activating ERK1 and ERK2 leading to activation of AP-
1, the signal transducer and activator of transcription 3 
(STAT3) and Lck. Another downstream kinase activated by DAG is 
PKCθ which regulates NF-kB activation. NF-kB functions in 
signaling for survival, function, and homeostasis of T cells. 
Other TFs activated downstream of TCR ligation are 
Ca2+/calmodulin dependent TF [54,55]. Ca2+ signaling also 
results in the activation of calcineurin which 
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dephosphorylates nuclear factor of activated T cells (NFAT) 
family members allowing for translocation into the nucleus for 
transcriptional activity [54,55,56]. There are several other 
events not fully understood which occur downstream of T cell 
ligation including cytoskeletal rearrangements and the 
formation of the immunological synapse (IS) [54,55]. 
 Costimulation is critical to activation through the TCR 
since TCR activation without costimulatory signals results in 
anergy. CD28 costimulatory signaling is the most robust and 
augments most signals already activated through the TCR alone 
resulting in a more quantitative signal that can impact 
signaling in a qualitative manner for distinct functional 
outcomes. Downstream signaling of CD28 includes activation of 
PI3K, Akt, and Ca2+ influx. Many of these pathways enhance 
nuclear translocation of NF-kB and NFAT [55,57]. Costimulation 
through CD28 also results in increased expression of the 
insulin transporter Glut1 which allows for increased glucose 
uptake and glycolysis. T cell activation also activates 
inhibitors of the pathway to modulate T cell activation. These 
include, but are not limited to, SHP-1 which dephosphorylates 
Lck, and HPK1 which inhibits SLP-76. Also increased expression 
of inhibitory receptors upon activation, such as PD-1 and 
CTLA-4, induce regulatory signaling through binding of their 
corresponding ligands [55]. 
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Another receptor capable of activating T cell signaling 
is the FGFR, which was discussed as one of the methods through 
which CD56 achieves downstream signaling in neurons (see NCAM 
in Neurons). The FGFR receptor is expressed by a subset of 
human T cells with low numbers in the peripheral blood 
[58,59,60]. Rheumatoid arthritis patients exhibit an increase 
in FGFR expression on T cells [61], an expression pattern also 
seen for CD56 [44] Studies have demonstrated the ability of 
FGFR stimulation in T cells with fibroblast growth factor 
(FGF) to activate AP-1, Lck, NFAT, as well as NF-kB. It is 
known that FGFR can stimulate activation of downstream 
signaling molecules associated with T cell activation such as 
PLC-γ1, Ras, and PI3-K [58,59]. These data demonstrate the 
presence of intact FGFR signaling in T cells provides a 
possible route through which CD56 can achieve signaling in T 
cells. Also since the second  pathway through which CD56 
signaling is achieved in neurons, Fyn/FAK, leads to activation 
of TCR associated signaling molecules as previously discussed 
(see NCAM in Neurons), it is possible that CD56 may have 
signaling capacity independent of FGFR in T cells. 
1.5 Significance 
T cells are an effective form of therapy as they are 
derived from the body’s natural immune defense system. The 
ability of T cells to proliferate, produce cytokines, and 
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effector molecules, traffic throughout the body, and to form 
memory cells means that T cell based therapies have the 
potential to be long lived and treat not only the primary 
tumor but metastases. The safety and efficacy demonstrated 
with CAR based immunotherapies [4,8] gives a foundation for 
applying CAR to new targets. There are some cancers which 
express T cell antigens including those expressing NCAM/CD56 
(discussed in section 1.3.3 NCAM and Cancer) and B-cell non-
Hodgkin Lymphoma which expresses CD38. Using T cells to target 
a T cell antigen seems counterintuitive in that the T cells 
would be susceptible to autolysis. Preliminary data 
demonstrates that CD56 positive T cells expressing a CD56-
specific CAR are not susceptible to autolysis. An 
understanding of this mechanism may enable us to broaden the 
application of CAR based immunotherapies to T cell antigens. 
Targeting T cell antigens not only has implications for cancer 
therapies but also for treating autoimmune diseases, which are 
hypothesized to be T cell mediated diseases, as well as for 
manipulation of transplants or to ablate the existing immune 
cells in a patient as an alternative to chemotherapy. 
1.6 Specific aims 
The overall goal of this dissertation is to generate 
chimeric antigen receptor modified T cells that are capable of 
targeting tumor expressed antigens that are also expressed on 
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T cells for use as an adoptive immunotherapy. The CD56 antigen 
is one such antigen and is the focus of this dissertation as 
it is highly and stably expressed by multiple malignancies 
while having normal expression on a subset of T cells. 
Although in normal unmanipulated PBMCs CD56+ T cells only 
represent 1-10% of the total cell population, at the end of a 
28 day expansion platform 48.65% ± 2.20% (mean ± SEM, n=4) of 
CD19-specific T cells co-express CD56. Consistent with CD56 
expression obtained on CD19CAR+ T cells, 45.03% ± 3.97% of 
CD56CAR+ T cells co-express the CD56 antigen at the end of 28 
days. This unexpected observation of CD56+CD56CAR+ T cells 
infers that these cells are unique in their survival capacity 
in a self-targeting scenario warranting a more detailed 
investigation of CD56CAR+ T cells. We want to understand if 
CD56 co-expression impacts their anti-tumor function, survival 
in relation to fratricide, as well as the direct effects on 
the CD56 antigen expressed. The central hypothesis of this 
dissertation study is that CD56 expression on CD56CAR+ T cells 
does not result in loss of CAR mediated lysis, fratricide or 
CD56 antigen modifications, but instead results in functional 
CD56-specific T cells capable of mediating anti-tumor 
responses.  
To evaluate this hypothesis we investigated the following 
aims: 
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Specific Aim 1- In vitro and in vivo validation of redirected 
cytolysis and anti-tumor capacity of CD56-specific T cells 
The CD56-specific CAR was generated using the single chain 
variable fragment (ScFv) from a humanized CD56 monoclonal 
antibody and fusing it to the signaling endodomains consistent 
with the second generation CAR (CD3ζ and CD28). To evaluate 
the function of the CD56CAR on T cells a CAR+ population of T 
cells was selectively expanded on aAPCs. The resulting cells 
were phenotypically characterized for memory and effector 
profiles, assessed for cytolysis and cytokine production in 
response to CD56+ tumor targets in vitro and evaluated for 
anti-tumor capacity in vivo in mouse xenograft studies. 
Specific Aim 2- Evaluation of the ability of CD56-specific CAR+ 
T cells to undergo fratricide 
Our co-culture platform results in the expansion of CD56CAR+ T 
cells that co-express the CD56 antigen. Since CAR functions 
independently of MHC, these cells should be capable of 
fratricide which could negatively impact the viability and 
function of the end product. To investigate self-targeting in 
CD56+CD56CAR+ T cells we evaluated expansion kinetics, 
maintenance and replenishment of CD56+CD56CAR+ T cells in 
culture and direct cytolysis and cytokine production in 
response to autologous cells. These studies required control 
CAR+ T cells that do not target a T-cell expressed antigen and 
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therefore do not target themselves. To this end we used CD19-
specific CAR+ T cells since they target a B cell expressed 
antigen and are well characterized in the literature. 
Specific Aim 3- Evaluating the CD56 antigen expressed on 
CD56CAR+ T cells 
The co-expression of CD56 and the CD56CAR is unexpected as 
others in the literature targeting a T cell expressed antigen 
with CARs either resulted in diminished antigen expression 
(CD30CAR) or observed autolysis (CD38CAR). In order understand 
how CD56CAR+ T cells can co-express the target antigen, CD56, 
we investigated the CD56 antigen expressed on the surface of 
CD56CAR+ T cells as compared to CD56 antigen expressed on 
CD19CAR+ T cells for any modifications that could result in 
evasion of self-targeting. To this end the CD56 antigen was 
evaluated for epitope loss through flow cytometry analysis 
with varying clones of CD56 specific mAbs and for direct 
modifications of the antigen achieved through differential PSA 
expression, N-linked glycosylation modifications, mutations or 
alternative splicing. 
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Chapter 2: In Vitro and In Vivo Validation of Redirected 
Cytolysis and Antitumor Capacity of CD56-Specific T cells 
2.1 Introduction  
 Tumors evade immune recognition through multiple 
mechanisms including down regulating major histocompatibility 
complex (MHC) expression, lacking co-stimulatory molecules 
necessary for T cells activation and defective antigen 
processing. Genetically modifying T cells to express receptors 
that redirect specificity and effector function can overcome 
these evasion techniques. Chimeric antigen receptors (CARs) 
are one such receptor, which achieves specificity for an 
antigen of choice independent of MHC through the combination 
of the single chain variable fragment (scFv) of a monoclonal 
antibody (mAb) and the signaling endodomains of a T cell 
receptor resulting in activation in response to engaging 
antigen [2,3,4,8,13,16,62]. There has been recent success in 
treating hematologic cancers with CAR-based immunotherapies, 
specifically for treating CD19+ malignancies [2,4,13,62,63]. 
CAR-based immunotherapies have been less successful in 
targeting solid tumors [8] with GD2-specific CAR+ T cells 
showing the most clinical success thus far [64,65].  
CARs are designed such that one CAR has the ability to 
target both solid and hematologic tumors and is not limited to 
application against one specific malignancy. The flexibility 
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of CAR application would be more effectively utilized if 
generated against a TAA expressed on multiple solid and 
hematologic tumors. The TAA CD56, aka neural cell adhesion 
molecule (NCAM), is one such antigen that has high and stable 
surface expression on a wide range of malignancies from NK 
cell leukemia to neuroblastoma [20].  
To test the hypothesis that one CAR can be generated to 
target both solid and hematologic malignancies a CD56-specific 
CAR, referred to as CD56CAR, was generated against using the 
scFv of a clinically relevant CD56-specific mAb [20,52,66]. 
These CD56CAR+ T cells were propagated on CD56+ aAPC generating 
a heterogeneous population of CD4+ and CD8+ memory and effector 
T cell subsets. In vitro cytokine production against and 
cytolysis of CD56+ tumor targets by CD56CAR+ T cells and the 
significant reduction of these responses in the presence of 
blocking antibodies demonstrate that CD56CAR+ T cells achieve 
specificity through CAR expression. These CD56CAR+ T cells 
significantly reduced tumor burden in vivo in mice with CD56+ 
neuroblastoma xenografts in models representing treatment of 
both minimal residual disease and bulk tumor burden resulting 
in enhanced overall survival as compared to control mice. This 
study demonstrates the clinical potential for CD56-specific 
CAR+ T cell application against a range of solid and 
hematologic malignancies.  
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2.2 Results: 
2.2.1 Generation and expansion of CD56-specific CAR+ T cells 
 To selectively expand CAR+ T cells post electroporation 
the culture is expanded on CD56 antigen positive aAPCs, K562 
clone 11.  One day following electroporation mock transfected 
“No DNA” control T cells did not express CAR on their cell 
membrane while T cells electroporated with the CD56CAR had 
40.53% ± 1.94% (mean ± SEM, n=4) CAR expression assessed by 
flow cytometry (Figure 1A). Following four rounds of 
stimulation, 28 days of culture, 97.56% ± 0.50% (n=4) of the T 
cells were CAR+ demonstrating the ability to expand a 
homogenous population of CD56CAR+ T cells. At the end of 28 
days there was a 25.54 ± 4.93 fold expansion (n=4) of CAR+ T 
cells in the culture and had all cells been taken forward in 
stimulations 4.34 x 1011 ± 3.46 x 1011 CAR+ T cells (n=4) would 
have been expanded (Figure 1B).  These data demonstrate the 
ability to stably express the CD56-specific CAR on CD3+ T cells 
and specifically expand out a large number of CD56CAR+ T cells.   
 
 
 
 
 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
 
Figure 1: Electroporation of CD56-Specific CAR into PBMCs.  
(A) Representative flow plot of CD56CAR expression on T cells 
24hrs post-electroporation versus a mock transfection as 
assessed by staining with an Fc-specific polyclonal antibody. 
(B) Inferred expansion kinetics of CD3+ T cells and CD56-
specifc CAR+ T cells in our co-culture system over 28 days. 
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2.2.2 Phenotypic profile of day 28 CD56CAR+ T cells 
T cells propagated for four weeks were assessed for cell 
surface markers to reveal their state of differentiation. Of 
the CD3+ CD56CAR+ T cells 95.10% ± 0.80% (n=4) were αβ T cells 
expressing either CD4+ (61.53% ± 14.58%, n=4) or CD8+ (34.70 ± 
13.45%). The T cells in these cultures did not express TCRVα24 
an NKT cell marker (Fig 2A). These CD56CAR+ T cells expressed 
32.70% ± 10.17% CXCR4 (n=4), a bone marrow homing receptor, 
16.07% ± 5.26% NKG2D (n=4), a marker associated with 
activation and effector function, but did not express the 
inhibitory receptors PD1 or PDL1 which are associated with 
exhaustion (Figure 2B). Effector memory, Tem (29.03% ± 4.69%, 
n=4) and central memory, Tcm (23.88% ± 3.06%, n=4) T cell 
populations were present in the culture as defined using 
expression of the surface markers CD95, CD28 and CD62L with 
CD95+CD28negCD62Lneg expression defining Tem and CD95+CD28+CD62L+ 
expression defining Tcm (Figure 2C). On average CD56CAR+ T 
cells expressed 99.68% ± 0.10% CD95, 68.55% ± 8.60% CD28, 
34.03% ± 4.80% CD62L, and 51.38% ± 4.70% CCR7 (n=4, Figure 
2C). These CD56CAR+ T cells also have high percentages of 
stored intracellular perforin and granzyme B in both the CD4+ 
and CD8+ T cells (Figure 2D). In sum these data portray the 
heterogeneity of CD56CAR+ T cells expanded at the end of 28 
days of co-culture, the capacity for in vivo persistence 
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through memory marker expression, and the capacity for 
cytolysis of tumor cells via granule release pathways 
(perforin/granzyme). 
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Figure 2: Day 28 phenotype of CD56-specific CAR+ T cells.  
(A) T cell subset markers, (B) Homing, activation and 
exhaustion markers and (C) Memory markers were assessed by 
flow cytometry. (D) Effector protein expression assessed by 
intracellualr flow cytometry. 
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2.2.3 In vitro cytotoxicity of CD56CAR+ T cells against CD56+ 
targets 
To directly assess the ability of  CD56CAR+ T cells to 
direct cytolysis to CD56+ tumor cells they were tested in a CRA 
at multiple effector to target (E:T) ratios against several 
tumor cell lines. Artificially generated control cell lines 
include EL-4, CD19+ EL-4, K562 Parentals and CD56+ Parentals, 
while Nalm-6 is a CD19+ B cell leukemia cell line used as a 
non-specific tumor target. Multiple CD56+ tumor cell lines were 
used as targets including neuroblastoma (CHLA-255, IMR-32, SK-
N-BE(2) and SK-N-SH) SCLC (HTB-119), NK cell leukemia (KHYG1) 
and glioma/astrocytoma (U87) cell lines (Figure 3A). At a 20:1 
effector to target ratio CD56CAR+ T cells significantly lysed 
all CD56+ targets (p <0.01) achieving as high as 64.85% ±  
0.13% specific lysis (n=4) while not significantly lysing any 
of the CD56neg targets (Figure 3B). These data demonstrate the 
capacity of CD56-specific CAR+ T cells to kill a wide range of 
CD56+ tumor cell lines shedding light on the breadth of 
possible clinical targets.  
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Figure 3:  In vitro killing of CD56+ targets by CD56-specific 
CAR+ T cells.  
(A) Expression levels of CD19 and CD56 on target cell lines as 
assessed by flow cytometry. (B) Redirected specificity of T 
cells expressing the CD56-specific CAR at day 28 as assessed 
by a 4 hour CRA at a 20:1 effector:target (E:T) ratio.  
Results of specific lysis are expressed as mean ± SEM of four 
donors. Significance analyzed using one-way ANOVA with 
Bonferroni’s Multiple Comparison post-test. 
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2.2.4 In vitro cytokine production by CD56CAR+ T cells in 
response to antigen 
 Cytokine production by T cells in the tumor 
microenvironment impacts the anti-tumor response achieved. 
Therefore we investigated the ability of CD56CAR+ T cells to 
respond to antigen stimulation with cytokine production. 
CD56CAR+ T cells were cultured alone “unstimulated”, with 
artificial stimulation through the PMA and Ionomyocin 
(PMA/IONO) with a leukocyte activation cocktail “LAC” or in 
the presence of targets with or without surface expression of 
CD56 for four hours and then assessed by intracellular flow 
cytometry for cytokine expression. In the presence of CD56+ 
targets a low percentage, although significant (p < 0.0001, 
n=4), of CD8+CD56CAR+ T cells expressed IL-10 as compared to 
their unstimulated counterpart while there was not a 
significant percentage of CD4+CD56CAR+ producing IL-10 (Figure 
4D). TGF-β and IL-4 are not produced by a significant 
percentage of CD4+ or CD8+ CD56CAR+ T cells in the presence of 
antigen (Figure 4E&F). The low percentage of CD56CAR+ T cells 
producing cytokines with functions in negatively regulating 
the immune response, such as IL-10 and TGF-β, infer the 
ability of CD56CAR+ T cells to self-regulate their immune 
function without inhibiting the overall anti-tumor response. 
The percentages of CD4+ and CD8+CD56CAR+ T cells producing IL-2 
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was variable in the presence of stimulation and this cytokine 
has the capacity to aid the antitumor response by stimulating 
T cell propagation and survival in vivo (Figure 4A). In 
contrast, cytokines that promote anti-tumor responses such as 
IFN-γ and TNF-α were produced by a highly significant 
(p<0.0001, n=4) percentage of both CD4+ and CD8+ CD56CAR+ T 
cells in the presence of CD56 antigen (Figure 4B&C). These 
data demonstrate the capacity of CD4+ and CD8+ CD56CAR+ T cells 
to produce a variety of in response to antigen. Not only was 
the ability to produce the cytokines investigated but using a 
multiplex luminex assay cytokine secretion of IL-10, IL-4, IL-
2, IFN-γ and TNF-α was confirmed and these results 
corresponded with that seen with the intracellular cytokine 
staining (Figure 5). These data highlight the capacity for 
CD56CAR+ T cells to produce and secrete high levels of 
cytokines (IL-2, IFN-γ and TNF-α) with the capacity to aid the 
in vivo anti-tumor response not only through acting on CD56CAR+ 
T cells, but on cells already in the tumor microenvironment 
through promoting survival, expansion, activation, antigen 
presentation and cytotoxicity [67]. 
 
 
 
 35 
 
 
 
 
 
 
 
 
 
 
 36 
 
Figure 4: Cytokine production profile of CD56-specific CAR+ T 
cells.  
Cytokine production of CD56CAR+ T cells was assessed at day 28 
either alone, with leukocyte activation cocktail (LAC), or in 
the presence of targets with and without antigen at a 1:5 
(E:T) ratio. Cytokine production of (A) IL-2, (B) IFN-γ, (C) 
TNF-α, (D) IL-10, (E) TGF-β and (F) IL-4 by CD4+ & CD8+ 
CD56CAR+ T cells was determined using intracellular cytokine 
analysis and the data are shown as the mean and SEM of four 
donors. Statistical analysis was analyzed using one-way ANOVA 
with Bonferroni’s Multiple Comparison post-test. 
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Figure 5: Cytokine secretion by CD56-specific CAR+ T cells.  
Cytokine secretion of IL-2, IFN-γ, TNF-α, IL-10, and IL-4 by 
CD56CAR+ T cells was assessed at day 28 either alone, with 
PMA/Ionomycin (PMA/IONO) or in the presence of targets with 
and without antigen at a 1:5 (E:T) ratio. Cytokine secretion 
was assessed using the Bio-Rad 27 Bio-Plex Kit and the data 
are shown as the mean and SEM of four donors.  
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2.2.5 Specificity of CD56CAR+ T cells achieved through the CAR 
 Unmodified T cells can be expanded and activated non-
specifically ex vivo resulting in anti-tumor responses. To 
demonstrate that cytolysis of CD56+ tumor targets by CD56CAR+ T 
cells is a result of CAR specificity, antibody based blocking 
experiments were performed. Intracellular cytokine assays were 
performed as described earlier except with untreated targets 
or targets treated with a CD56-specific antibody to block CAR 
binding the antigen. IFN-γ production was unaffected in the 
negative and positive controls in the presence of the blocking 
antibody, as expected, since the LAC activates the T cell 
independent of the CAR and antigen. IFN-γ production in 
CD4+CD56CAR+ T cells was significantly diminished (p<0.01, n=4) 
against all CD56+ targets achieving as high as 93.14% ± 1.87% 
reduction in the presence of the blocking antibody (Figure 
6A). IFN-γ production by CD8+CD56CAR+ T cells was also 
significantly diminished (p<0.001, n=4) against all CD56+ 
targets except CD56+ K562 Parentals and  HTB-119 achieving as 
high as 80.34% ± 3.32% reduction in the presence of the 
blocking antibody (Figure 6A). The same assay was performed to 
analyze the ability to block TNF-α production by CD4+ and 
CD8+CD56CAR+ T cells and the same trend of diminished cytokine 
production was seen in the presence of the CD56-specific 
blocking antibody (data not shown). These results demonstrate 
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that effector cytokine production by CD56CAR+ T cells is 
significantly achieved through CAR specificity for the CD56 
antigen. To further evaluate the specificity of the CAR 
blocking experiments were performed in CRAs setup as described 
earlier except at a lower E:T ratio with or without a CD56-
specific ability to block lysis through the CAR. As expected 
percent lysis by CD56CAR+ T cells was significantly diminished 
(p<0.01, n=4) against all CD56+ targets and almost eliminated 
by the addition of the blocking antibody with as great as 
95.42% ± 2.29% reduction in killing (Figure 6B). In sum these 
data confirm that CD56CAR+ T cells are indeed achieving CD56 
targeted specificity through the CAR. 
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Figure 6: Specificity of the CD56-specific CAR. 
Day 28 intracellular cytokine assay for (A) IFN-γ (mean ± SEM 
of 4 donors) expression in response to targets at a 1:5 (E:T) 
ratio with or without blocking antibody. (B) CRA at a 2:1 
(E:T) ratio against target with or without antibody (mean ± 
SEM of 4 donors). Statistical analysis performed using one-way 
ANOVA with Bonferroni’s Multiple Comparison post-test. 
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2.2.6 In vivo anti-tumor efficacy of CD56CAR+ T cells 
 To evaluate the inpatient potential of CD56CAR+ T cells, 
anti-tumor capacity was evaluated in vivo.  To assess the 
ability of CAR+ T cells to target a range of tumor burdens, we 
established two tumor models. One model with “high” tumor 
burden defined by the visualization of tumor through BLI at 
the time of  the first T cell injection (Figure 7) and one 
with “low” tumor burden where T cell infusions were begun two 
days post-tumor infusion (Figure 9). In the “high” burden 
model NSG mice were I.V. injected with neuroblastoma cells and 
mice that received three infusions of CD56CAR+ T cells with 
recombinant human IL-2 at days 21, 28, and 35 had 
significantly reduced tumor burden (p<0.0001, n=5) as compared 
to tumor only untreated mice. At day 32 the tumor burden in 
the T cell treated mice was 1.08 x 107p/s ± 1.79 x 106p/s which 
was significantly reduced as compared to the tumor burden of 
the tumor only mice which was 9.87 x 107p/s ± 2.13 x 107p/s, as 
measured by flux of the tumor cells (Figure 8A&B). The tumor 
only mice died earlier than T-cell treated mice, demonstrating 
that treatment of neuroblastoma with CD56CAR+ T cells 
significantly increases the overall survival of the mice 
(p=0.0042, n=5, Figure 8C). In the “low” burden studies a 
total of three T cell infusions were administered once every 
seven days beginning two days post tumor injection. In these 
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mice, those treated had significantly delayed tumor growth 
based upon flux analysis (p<0.0001, n=9) specifically 
achieving significant reduction in tumor burden at days 28 and 
32 (p<0.01 and p<0.0001 respectively, n=9, Figure 10A&B) and 
had a significantly improved overall survival (p<0.0001, n=9, 
Figure 10C) as compared to the tumor only group. In sum these 
data demonstrate the significant in vivo anti-tumor capacity 
of CD56CAR+ T cells inferring potential benefit as a treatment 
in the clinic. 
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Figure 7: Schematic of experimental design for “high” tumor 
burden model. 
NSG mice were challenged I.V. with 1e6 neuroblastoma cells, 
CHLA-255, expressing firefly luciferase for bioluminescant 
imaging, BLI. The tumor only group was left untreated post 
tumor infusion while the Tumor + T cell group was treated once 
a week with 10e7 CD56-specific CAR+  T cells starting at day 21 
post-tumor for a total of three infusions. Il-2 was 
administered post T cell infusion and 2x the following day at 
60,000 units. The T cell only group received T cells and IL-2 
on the same days as the Tumor + T cell group and served as a 
control for T cell safety.   
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Figure 8: In vivo anti-tumor efficacy of CD56CAR+ T cells 
against “high” tumor burden.  
(A) Image of flux (representing tumor) in mice at day 32 where 
the T cell treated group has significantly less tumor burden.  
(B) Measured flux of the tumor cells in the mice using BLI. 
Significance between treatment groups is p<0.0001 (analyzed 
using two way RM-ANOVA with a Bonferroni post-test).  
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Figure 9: Schematic of experimental design for “low” tumor 
burden model.  
NSG mice were challenged I.V. with 1e6 neuroblastoma cells, 
CHLA-255, expressing firefly luciferase for bioluminescant 
imaging, BLI. The tumor only group was left untreated post 
tumor infusion while the Tumor + T cell group was treated once 
a week with 10e7 CD56-specific CAR+  T cells starting at day 2 
post-tumor for a total of three infusions. Il-2 was 
administered post T cell infusion and 2x the following day at 
60,000 units. The T cell only group received T cells and IL-2 
on the same days as the Tumor + T cell group and served as a 
control for T cell safety.   
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Figure 10: In vivo anti-tumor efficacy of CD56CAR+ T cells 
against “low” burden.  
(A) Image of flux (representing tumor) in mice at day 32 where 
the T cell treated group has significantly less tumor burden.  
(B) Measured flux of the tumor cells in the mice using BLI. 
Significance between treatment groups is p<0.0001 (analyzed 
using two way RM-ANOVA with a Bonferroni post-test).  
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2.3 Discussion  
Our data show the ability to generate CD56-specific CAR+ T 
cells to clinically relevant numbers in 28 days of co-culture. 
The resulting CD56CAR+ T cells consist of a heterogeneous 
population of T cells that produce and secrete homeostatic 
(IL-2) and effector (IFN-γ and TNF-α) cytokines in response to 
antigen stimulation. CD56-speicific CAR+ T cells also 
demonstrated significant lysis against multiple CD56+ tumor 
cell lines, both solid and hematological, in vitro. Blocking 
antibody studies implicated CAR specificity to be responsible 
for cytokine production and lysis responses in vitro. In vivo 
CD56CAR+ T cells significantly reduced tumor burden whether 
“low” or “high” and improved overall survival of mice with 
CD56+ neuroblastoma xenografts as compared to control mice.  
These studies discussed have demonstrated a multitude of 
clinically relevant capacities of CD56-specific T cells both 
in vitro and in vivo. The co-culture system of CAR+ T cells on 
aAPCs expands a variety of cells including central and 
effector memory T cells. These varied T cell phenotypes may 
allow for an immediate anti-tumor response as well as the 
formation of memory and enhance T cell survival through 
production of cytokines improving the potential for a long-
lived therapeutic effect [68,69,70]. The CAR+ T cells have been 
demonstrated to have CAR-mediated specificity and cytotoxic 
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capacity for CD56 through antibody blocking experiments to 
assure only antigen-specific responses.  
 The mouse model demonstrates the ability of T cells given 
I.V. to target and kill tumor in vivo providing an anti-tumor 
response resulting in enhanced overall survival. Although 
significant, improved survival did not result in cure as the 
mice did succumb to death due to tumor burden. The T cell 
cytokine support needed for survival and homing of CD56CAR+ T 
cells is lacking in the mouse and could account for the 
inability to cure. The ability of CD56-specific T cells to 
generate an anti-tumor effect under such conditions shows 
promise for future use in the clinic.  
 The success of the GD2-specific CAR in clinical trials 
achieving complete responses in 3 of 19 patients [65] shows 
promise for CAR-based immunotherapies for the treatment of 
solid tumors, an area of study achieving minimal successes 
thus far [8]. Although clinical responses were achieved in the 
GD2 CAR clinical trials, this study utilizes a first 
generation CAR [65] and our studies improve upon this by 
utilizing a second generation CAR which previous studies 
demonstrate to have enhanced functionality and survival 
capacity [2,4,13,16,62]. Several previous studies indicate 
enhanced in vivo persistence of T cell products consisting of 
CD4 helper, effector memory and central memory T cells 
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[2,68,69,70]. Demonstrated in figure 2, our expansion system 
consistently results in CAR+ products representing a 
combination of all three of these of these cell subsets 
inferring the capacity for enhanced in vivo survival capacity. 
 The clinical potential of CD56-specific CAR+ T cells is 
not limited to treating neuroblastoma as we have demonstrated 
the wide range of tumor targets in vitro. The functional anti-
tumor capacity of CD56-specific T cells in vivo is indicative 
of potential for clinical translation and can easily be 
combined with already existing therapies to enhance anti-tumor 
efficacy. In sum CD56-specific CAR+ T cells can be expanded to 
clinically relevant numbers and demonstrate in vitro and in 
vivo anti-tumor capacity as well as CAR directed specificity. 
These T cells have clinical potential as a therapy against 
multiple malignancies. 
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Chapter 3: Evaluation of the ability of CD56-Specific CAR+ T 
cells to undergo fratricide 
3.1 Introduction 
 Some tumor associated antigens are also expressed on T 
cells, which may preclude the development of T cell based 
immunotherapies against these antigens since there is the 
potential for autolysis. The CD56 antigen is a T cell 
expressed antigen associated with activation and effector 
potential in T cells. High and stable expression of CD56 on 
several deadly malignancies makes this TAA an attractive 
target [20].  
 The TAA CD56 is also a T cell expressed antigen 
[31,34,35]. Although not commonly a T cell identifying marker 
as CD56 is for NK cells, CD56 is up-regulated and expressed on 
the surface of activated T cells [36,37,38]. Studies 
evaluating the role of CD56 on T cells remain scarce even 
though its expression was identified decades ago. CD56 
expression on T cells has been correlated with MHC 
unrestricted cytotoxicity [34,35,36,37,38], aging [39,40,41] 
and reduced proliferative capacity [37,39]. One study even 
demonstrated signaling capacity of this surface antigen and 
their data inferred the ability for the signaling pathway to 
synergizes with that achieved through the CD3 [44]. In our 
aAPC co-culture system of growing CAR+ T cells CD56 expression 
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increases by day 28 of culture. We have constructed and 
expressed a CD56-specific CAR on T cells which redirects 
specificity of the T cells to CD56+ tumor targets both in vitro 
and in vivo (see chapter 2). In our studies we consistently 
generate a subset of CD56CAR+ T cells that co-express the CD56 
antigen on their cell surface similarly to CD19CAR+ T cells 
which target a non-T cell expressed TAA.  
Since the CAR, by design, targets antigen irrespective of 
MHC, in theory autologous CD56CAR+ T cells in culture should 
have the capacity to kill each other if they express the CD56 
antigen, undergo fratricide. Studies of CARs targeting T cell 
expressed antigens are minimal and the results in reference to 
autolysis or fratricide vary. Mihara et al. cultured their 
CD38-specific CAR+ T cells in the presence of blocking 
antibodies in order to prevent autolysis [18] while Salvoldo 
et al. report low CD30 expression on their CD30-specifc CAR+ T 
cells resulting in a lack of autolysis [21]. Therefore the in 
vivo survival capacity of these cells should not be negatively 
impacted by self-targeting as it has not affected the cells in 
vitro.  
 Since these T cells are simultaneously expressing the 
CD56 antigen and CD56-specific CAR we want to investigate if 
these cells undergo autolysis. In this aim we demonstrate that 
in comparison to CD19-specific CAR+ T cells (non-self-
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targeting), CD56-specific CAR+ T cells expand similarly with 
respect to total CAR+ T cells as well as CD56+CAR+ T cells. Not 
only do expansion kinetics follow closely to that of CD19-
specific CAR+ T cells, CD56neg CD56-specific CAR+ T cells will 
replenish a CD56+ fraction of CAR+ T cells and CD56+ CD56-
specific CAR+ T cells will maintain CD56 expression similarly 
to that seen with CD19-specific CAR+ T cells. Our studies infer 
that CD56-specific CAR+ T cells do not undergo autolysis as 
they do lyse CD56+CD56CAR+ T cells. The lack of effector 
cytokine production, specifically IFN-γ, in response to CD56 
antigen on autologous cells implies that CD56+CD56CAR+ T cells 
do not recognize themselves as targets. 
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3.2 Results: 
3.2.1 Expression of the CD56 antigen on CD56CAR+ T cells 
 Co-expression of CD56 on CD19CAR+ T cells is expected 
since T cells up regulate CD56 expression upon activation. 
Since CAR specificity is irrespective of MHC, it is expected 
that CD56CAR+ T cells will not survive in the culture if they 
co-express the CD56 antigen due to self-targeting a.k.a. 
fratricide or autolysis.  
 As expected CD19CAR+ T cells co-express the CD56 antigen 
on a subset of cells, but unexpectedly the CD56+ T cells in the 
CD56CAR+ cultures also co-express the CAR (Figure 11A). One day 
following electroporation 0.59% ± 0.19% (mean ± SEM, n=4) of 
CD19CAR+ T cells co-express the CD56 antigen while 0.46% ± 
0.14% of CD56CAR+ T cells co-express the CD56 antigen. After 
four stimulations on aAPCs, 28 days of co-culture, 47.74% ± 
2.15% of CD19CAR+ T cells co-express CD56 compared to 44.77% ± 
3.99% of CD56CAR+ T cells (Figure 11B). The co-expression of 
CAR and CD56 on CD19CAR+ T cells versus on CD56CAR+ T cells is 
not significantly different (Day 0 p=0.6229, Day 28 p=0.6261). 
Similar percentages of CD56+ T cells in CD56CAR+ T cells as 
compared to CD19CAR+ T cells infers that CD56+CD56CAR+ T cells 
are surviving in the culture despite the hypothesized capacity 
for self-lysis.  
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Figure 11: Co-expression of CD56 on CAR+ T cells.  
(A)Schematic of gating to demonstrate CD56 and CAR co-
expression on CD3+ cells. LEFT PLOTS: CD56 expression in the 
bulk day 28 CD19CAR (TOP) and CD56CAR (BOTTOM) cultures. Gate 
is on CD3+CD56+ T cells. RIGHT PLOTS: CAR co-expression on the 
CD56+ fraction of CD3+ T cells. This is one representative 
donor of four. (B) Percent co-expression of CD56 and CAR on 
CD19CAR+ and CD56CAR+ T cells at days 0 and 28 of co-culture as 
assessed by flow cytometry. Data are shown as the mean ± SEM 
of four donors. Significance analyzed using two-tailed t-
tests.  
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3.2.2 Effects of co-expression on expansion kinetics 
 CD38 is expressed on activated T cells [71] and on 
approximately all of our CD56CAR+ T cells (See Chapter 2, 
Figure 2). CD38-specific T cells could not be expanded without 
the addition of a CD38-specific antibody to the culture to 
block autolysis [18]. To understand if co-expression of the 
CD56 antigen on CD56CAR+ T cells is negatively impacting the 
expansion of CD56CAR+ T cells we compared CD56CAR+ T cell 
expansion kinetics to that of CD19CAR+ T cells. If 
CD56+CD56CAR+ T cells are being killed in the culture it is 
expected that it will result in reduced expansion of CAR+ T 
cells as a consequence of fratricide. At the end of 28 days of 
co-culture we expand 1.07 x 1012 ± 3.38 x 1011 (n=4) CD19CAR+ T 
cells as compared to 8.84 x 1011 ± 7.23 x 1011 (n=4) CD56CAR+ T 
cells. These data demonstrate that simultaneous expression of 
the CD56 antigen on CD56CAR+ T cells does not significantly 
(p=0.8256) effect their overall expansion kinetics as compared 
to T cells without self-targeting capacity (Figure 12A). To 
further investigate the impact of the expression of CD56 on 
CD56CAR+ T cells we compared the expansion kinetics of 
CD56+CAR+ T cells in CD19CAR+ T cells to those of CD56CAR+ T 
cells. At the end of 28 days of co-culture we expand 5.25 x 
1011 ± 1.74 x 1011 (n=4) CD56+CD19CAR+ T cells as compared to 
3.49 x 1011 ± 2.73 x 1011 (n=4) CD56+CD56CAR+ T cells. Therefore 
the expansion kinetics of CD56+CAR+ T cells is not 
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significantly (p=0.6084) different between CD19CAR+ and 
CD56CAR+ T cells (Figure 12B). These data demonstrate that the 
expansion kinetics of CD56CAR+ T cells is not negatively 
impacted by the co-expression of the CD56 antigen on CD56CAR+ T 
cells and strongly support the hypothesis that CD56CAR+ T cells 
are not undergoing autolysis.   
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Figure 12: Comparison of expansion kinetics of CD19CAR+ and 
CD56CAR+ T cells.  
The inferred expansion kinetics of (A) CD3+CAR+ T cells and (B) 
CD3+CD56+CAR+ T cells in CD19CAR and CD56CAR cultures over 28 
days of in vitro co-culture with aAPCs. Data are shown as the 
mean ± SEM of four donors and significance was analyzed using 
two-way RM ANOVA.  
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3.2.3 The Role of CD56negCD56CAR+ T cells in the maintenance of 
CD56+CD56CAR+ T cells 
 The expansion kinetics of CD56+ T cells in both CD19CAR+ 
and CD56CAR+ T cells show no significant differences inferring 
that CD56+CD56CAR+ T cells are surviving and expanding in 
culture. These expansion kinetics studies were performed on 
bulk CAR+ populations, meaning they contained both CD56neg and 
CD56+ CAR+ T cells. Upon activation CD56neg T cells can give 
rise to CD56+ T cells. CD56+ T cells can proliferate but 
studies demonstrate them to have reduced proliferative 
capacity. In order to more closely evaluate the survival and 
expansion capacity of CD56+CAR+ T cells we sorted day 28 CAR+ 
cultures into CD56neg and CD56+ fractions (Figure 13A) and 
followed CD56 expression and the expansion kinetics of both 
fractions though two stimulations (14 days).  
 CD19CAR+ T cells were used as control cells for 
comparison. It is expected that CD56neg cells will proliferate 
exponentially and give rise to CD56+ T cells while CD56+ T 
cells will expand and maintain CD56 expression. If CD56CAR+ T 
cells are not performing autolysis the expansion kinetics and 
CD56 expression on CD56CAR+ T cells from both fractions should 
closely mirror those seen for CD19CAR+ T cells. If CD56CAR+ T 
cells do lyse themselves it is expected that the CD56neg 
fraction will have diminished expression of CD56 on the T 
cells and diminished expansion kinetics, while the CD56+ 
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fraction will have minimal if any expansion and/or loss of 
CD56 expression.  
 As expected the CD56neg fraction of CD19CAR+ T cells 
starting out as only 7.24% ± 0.94% (mean ± SEM, n=4) CD56+ 
following sorting were 59.28% ± 2.08% CD56+ by the end of the 
two stimulation cycles. The CD56neg fraction of CD56CAR+ T cells 
started out 10.91% ± 3.21% CD56+ following sorting and were 
37.23% ± 7.10% CD56+ after the 14 days of co-culture (Figure 
13B). Both CD56neg fractions of CAR+ T cells regenerated a CD56+ 
fraction of CAR+ T cells with no significant difference 
(p=0.2035)in the percent CD56 expression or the overall 
expansion kinetics (p=0.3802) throughout the two stimulations 
Figure 13C). These data demonstrate that the CD56neg fraction 
of CAR+ T cells can give rise to CD56+ T cells and has the 
capacity to repopulate a CD56+ fraction of T cells upon 
removal. This capacity of regeneration demonstrates the 
possibility for CD56negCD56CAR+ T cells to compensate for 
autolysis of CD56+CD56CAR+ T cells in the culture. Although 
since the expansion kinetics between CD19CAR+ T cells and 
CD56CAR+ T cells are not significantly different and CD56CAR+ T 
cells are not regaining CD56 expression faster than CD19CAR+ T 
cells it is unlikely that the CD56neg fraction is solely be 
responsible for the presence of CD56+CD56CAR+ T cells in the 
culture. 
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 The CD56+ fraction of CD19CAR+ T cells started out 97.08% 
± 0.18% CD56+ following the sort and were 88.28% ± 1.23% CD56+ 
14 days post-sort. Similarly the CD56+ fraction of CD56CAR+ T 
cells starting out 97.65% ± 0.25% CD56+ after sorting were 
78.80% ± 0.91% CD56+ at 14 days (Figure 13B). The percent 
CD56+CAR+ T cells was significantly different between CD19CAR+ 
and CD56CAR+ T cells (p=0.0120) while the expansion kinetics of 
these cells were not significantly different (p=0.4089, Figure 
13C). These data support the hypothesis that CD56+CD56CAR+ T 
cells do not undergo fratricide as not only do CD56+CD56CAR+ T 
cells maintain CD56 expression, they expand upon stimulation. 
In sum these data demonstrate that although the CD56neg 
fraction of CAR+ T cells gives rise to CD56+CD56CAR+ T cells 
they are not solely responsible for the maintenance and 
expansion of CD56+CD56CAR+ T cells in the co-culture. 
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Figure 13: The expansion kinetics and CD56 expression on 
sorted CD56neg and CD56+ CAR+ T cells.  
(A)Flow plots illustrating CD56 expression on bulk CD19CAR+ 
(TOP MIDDLE) and CD56CAR+ (BOTTOM MIDDLE) T cells and the 
resulting CD56 expression on the CD56neg fractions (LEFT) and 
CD56+ fractions (RIGHT) of CAR+ T cells following magnetic bead 
separation. Shown is one representative donor of four. The (B) 
percent CD56 expression and (C) The inferred expansion 
kinetics on CD56neg (LEFT) and CD56+ fractions of CAR+ T cells 
over fourteen days of co-culture. Data are shown as the mean ± 
SEM of four donors and significance was analyzed using two-way 
RM ANOVA. 
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3.2.4 Evaluation of fratricide by CD56CAR+ T cells 
 T cells are capable of killing T cells. Since CAR 
functions irrespective of MHC in theory any CD56+ target should 
be recognized by a CD56CAR+ T cell as a target and as a result 
lysed. Therefore CD56+CD56CAR+ T cells should be recognized as 
targets by CD56CAR+ T cells and lysed as a result of 
fratricide.  
 A CRA using autologous cells as targets was performed to 
determine if CD56neg and/or CD56CAR+ T cells could lyse 
CD56+CD56CAR+ T cells. CD19CAR+ T cells were used as control 
effector T cells since they do not target a self-expressed 
antigen. In order to generate autologous CD19+ targets we 
expressed tCD19 under hygromycin selection in autologous T 
cells in T cells (1) without CAR, (2) in combination with the 
CD19CAR and (3) in combination with the CD56CAR. Despite the 
selective pressure of hygromycin we were unable to generate 
CD19+CD19CAR+ T cells but CD19 was successfully expressed on T 
cells without CAR as well as on CD56CAR+ T cells (Figure 
14A&B). We hypothesize that CD19CAR+ T cells selectively 
degrade the tCD19 protein to prevent autolysis. Magnetic bead 
sorting based upon CD56 antigen expression separated the 
CD56neg T cells from CD56+ T cells. This sorting enabled us to 
generate autologous CD56neg and CD56+ (1) CARneg T cells (No 
DNA), (2) CD19CAR+ T cells, and (3) CD56CAR+ T cells. NK cells 
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which are naturally CD56+ were used as another autologous 
control target. 
 Bulk unsorted CD19CAR+ T cells and CD56CAR+ T cells were 
used as effectors. Expected results are for CD19CAR+ T cells to 
lyse all CD19+ targets irrespective of CAR expression and for 
CD56CAR+ T cells to lyse all CD56+ targets irrespective of CAR 
expression. All CD19+ targets are significantly lysed (tCD19 
CD56neg T cells and tCD19 CD56CAR+ CD56neg T cells, p<0.0001, 
n=4) by CD19CAR+ T cells while all CD19neg targets are not 
significantly lysed (Figure 15). These data demonstrate the 
capacity for T cells to target and lyse autologous T cells as 
well as the ability of CD56CAR+ T cells to be lysed. CD56CAR+ T 
cells significantly lysed all CD56+ targets (NK cells, CD56+ No 
DNA T cells, and CD56+CD19CAR+ T cells, p<0.0001, n=4) except 
for CD56+CD56CAR+ T cells, while not significantly lysing any 
CD56neg targets (Figure 15). These data demonstrate the ability 
of CD56CAR+ T cells to lyse autologous T cells with or without 
CAR while highlighting the capacity of CD56+CD56CAR+ T cells to 
evade being lysed. This data strongly suggests that 
CD56+CD56CAR+ T cells do NOT perform autolysis.  
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Figure 14: The expansion and CD19 expression on artificially 
generated autologous tCD19+ targets.  
(A)Inferred expansion kinetics of CD3+ and CAR+ T cells in 
tCD19 (TOP), tCD19CD19CAR (MIDDLE) and tCD19CD56CAR (BOTTOM) 
cultures over 28 days of culture. (B) The percent CD19 
expression on tCD19 (TOP), tCD19CD19CAR (MIDDLE) and 
tCD19CD56CAR (BOTTOM) T cells at day 28. Shown is one 
representative donor of four. 
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Figure 15: Cytotoxicity of CD19CAR+ and CD56CAR+ T cells 
against autologous targets. 
Redirected specificity of CAR+ T cells (CD19CAR+ (TOP) and 
CD56CAR+ (BOTTOM)) against autologous targets at day 35 
assessed by a 4 hour CRA at a 40:1 E:T ratio. All cells used 
are from the same donor (AUTOLOGOUS).  The bottom table 
illustrates expression of the CD56 antigen, CD19 antigen, 
CD19CAR and CD56CAR on each target. A minus sign (-) indicates 
≤10% expression and a plus sign (+) indicates ≥85% expression, 
while a (-*) indicates ≤25% expression. Results of specific 
lysis are expressed as mean ± SEM of four donors. Significance 
analyzed using one-way ANOVA with Bonferroni’s Multiple 
Comparison post-test.  
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3.2.5 Activation of CD56CAR+ T cells in response to autologous 
antigen expression 
 The production of IFN-γ is one functional output of T 
cell activation [72]. Since CD56+CD56CAR+ T cells are not being 
lysed by CD56CAR+ T cells we want to determine if CD56CAR+ T 
cells are activated by CD56+CD56CAR+ T cells. Effector T cells 
alone were used for a baseline readout of IFN-γ producing 
cells and the addition of PMA/IONO to the effectors was used 
as a non-specific activator of the T cells to provide a 
positive control for the maximum percent IFN-γ producing 
cells. Using the same autologous targets as discussed for the 
CRA in 3.2.4 the percent IFN-γ producing cells was assessed by 
flow cytometry. 
 The percent of IFN-γ producing CD19CAR+ T cells was 
significantly increased in response to tCD19 CD56neg T cells 
and tCD19 CD56CAR+ CD56neg T cells in both CD4+ (p<0.001) and 
CD8+ (p<0.001 and p<0.01 respectively) populations (Figure 16, 
TOP). The percent of IFN-γ producing CD56CAR+ T cells, both 
CD4+ and CD8+, significantly increased in the presence of all 
CD56+ targets (NK cells, CD56+ No DNA T cells, and CD56+CD19CAR+ 
T cells, p<0.0001, n=4) except for CD56+CD56CAR+ T cells 
(Figure 16, BOTTOM). CD19CAR+ T cells did significantly 
increase the percent CD8+ IFN-γ producing T cells in response 
to NK cells (p<0.01), but otherwise had no significant 
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increase in IFN-γ against any CD19neg targets. CD56CAR+ T cells 
did not significantly increase the percent IFN-γ producing 
cells in response to any CD56 negative targets. 
In addition to IFN-γ production, activated T cells up-
regulate the cell surface marker CD69, a marker of early 
activation [73], as well as CD107a, which is a marker of 
degranulation [74] and T cells that perform fratricide have 
been described to use perforin as the mechanism of lysis[22]. 
To further investigate activation of CD56CAR+ T cells in 
response to CD56+CD56CAR+ T cells we evaluated CD69 and CD107a 
up-regulation on CD19CAR+ and CD56CAR+ T cells in response to 
the same autologous targets used for the IFN-γ assays. 
Similarly to IFN-γ production, CD69 and CD107a expression was 
significantly up-regulated by CD19CAR+ T cells in response to 
CD19+ targets but not CD19 negative targets and by CD56CAR+ T 
cells in response to all CD56+ targets except CD56+CD56CAR+ T 
cells but not in response to CD56 negative targets (CD69 
expression-Table 1 and CD107a expression-Table 2). In sum 
these data support the hypothesis that CD56CAR+ T cells are not 
activated by the CD56 antigen on CD56+CD56CAR+ T cells and 
strongly suggest that CD56CAR+ T cells do not recognize 
CD56+CD56CAR+ T cells as targets resulting in evasion of 
autolysis.  
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Figure 16: IFN-γ production by CD19CAR+ and CD56CAR+ T cells in 
response to autologous targets.  
IFN-γ production of CAR+ T cells (CD19CAR+ (TOP) and CD56CAR+ 
(BOTTOM)) was assessed at day 35 either alone, with leukocyte 
activation cocktail (LAC), or in the presence of autologous 
targets with and without antigen at a 1:5 (E:T) ratio. IFN-γ 
production by CD4+ (LEFT) & CD8+ (RIGHT)CAR+ T cells was 
determined using intracellular cytokine analysis and the data 
are shown as the mean and SEM of four donors. Statistical 
analysis was analyzed using one-way ANOVA with Bonferroni’s 
Multiple Comparison post-test. 
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TARGETS CD19CAR (Mean ± SEM, sig.) CD56CAR (Mean ± SEM, sig.)
Alone 1.14 ± 0.16 1.33 ± 0.2591
PMA/IONO 38.73 ± 5.29, **** 16.18 ± 2.84, ****
No DNA CD56neg 0.85 ± 0.31 3.85 ± 1.10
No DNA CD56+ 1.39 ±  0.20 11.47 ± 3.06, ****
NK Cells 4.99 ± 1.39 11.23 ±  2.75, ****
tCD19 11.32 ±  2.96, * 4.25 ± 1.39
CD19CAR CD56neg 0.71 ± 0.16 3.10 ± 0.95
CD19CAR CD56+ 1.21 ± 0.17 10.42 ± 2.82, ***
CD56CAR CD56neg 2.19 ± 0.36 1.04 ± 0.30
CD56CAR CD56+ 3.95 ± 0.16 2.43 ± 0.83
tCD19CD56CAR CD56neg 15.41 ± 4.12, *** 0.96 ± 0.19
Percent CD107a
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Table 1: CD107a up-regulation by CD19CAR+ and CD56CAR+ T cells 
in response to autologous targets.  
CD107a expression on CAR+ T cells (CD19CAR+ and CD56CAR+) was 
assessed at day 35 either alone, with PMA/IONO, or in the 
presence of autologous targets with and without antigen at a 
1:5 (E:T) ratio. CD107a expression on CD8+ CAR+ T cells was 
determined using flow cytometry analysis and the data are 
shown as the mean and SEM of four donors. Statistical analysis 
was analyzed using one-way ANOVA with Bonferroni’s Multiple 
Comparison post-test. Pink highlighted boxes represent 
significant increases in CD107a expression. 
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TARGETS CD4 CD8 CD4 CD8
Alone 51.83 ± 4.48 58.48 ± 7.80 48.83 ± 10.72 50.60 ± 8.68
PMA/IONO 87.67 ± 7.01, **** 93.65 ± 2.14, **** 83.03 ± 3.19, ** 85.27 ± 6.00, ***
No DNA CD56neg 51.08 ± 4.10 59.03 ± 6.61 53.85 ± 8.44 58.85 ± 11.56
No DNA CD56+ 51.38 ± 3.50 63.18 ± 7.84 84.95 ± 2.13, *** 74.15 ± 10.62, *
NK Cells 59.88 ± 2.69 74.70 ± 5.25 87.73 ±  1.28, *** 76.60 ±  9.84, *
tCD19 86.38 ±  2.15, **** 91.73 ±  1.80, **** 54.38 ± 9.77 61.53 ± 11.50
CD19CAR CD56neg 51.80 ± 3.89 60.13 ± 6.50 55.25 ± 8.41 61.00 ± 10.60
CD19CAR CD56+ 52.55 ± 3.99 63.78 ± 7.84 86.78 ± 1.56, *** 76.05 ± 9.32, *
CD56CAR CD56neg 56.40 ± 4.89 57.45 ± 5.74 46.93 ± 9.93 51.58 ± 8.73
CD56CAR CD56+ 66.00 ± 6.76 60.98 ± 10.25 49.80 ± 10.83 58.95 ± 9.74
tCD19CD56CAR CD56neg 87.88 ± 2.41,**** 69.38 ± 7.13 52.85 ± 8.72 55.13 ± 5.58
Percent CD69
CD19CAR (Mean ± SEM, sig.) CD56CAR (Mean ± SEM, sig.)
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Table 2: CD69 up-regulation by CD19CAR+ and CD56CAR+ T cells in 
response to autologous targets.  
CD69 expression on CAR+ T cells (CD19CAR+ and CD56CAR+) was 
assessed at day 35 either alone, with PMA/IONO, or in the 
presence of autologous targets with and without antigen at a 
1:5 (E:T) ratio. CD69 expression on CD4+ and CD8+ CAR+ T cells 
was determined using flow cytometry analysis and the data are 
shown as the mean and SEM of four donors. Statistical analysis 
was analyzed using one-way ANOVA with Bonferroni’s Multiple 
Comparison post-test. Pink highlighted boxes represent 
significant increases in CD69 expression. 
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3.3 DISCUSSION 
 In this aim we demonstrated that CD56 is expressed on a 
subset of CD56CAR+ T cells and that this co-expression does not 
significantly negatively impact the overall expansion kinetics 
of CAR+ or CD56+CAR+ T cells in the culture as compared to 
CD19CAR+ T cells. Our data show that although CD56negCD56CAR+ T 
cells generate CD56+CD56CAR+ T cells, they are not solely 
responsible for the existence of CD56+CD56CAR+ T cells in the 
culture since CD56+CD56CAR+ T cells not only maintain CD56 
expression, but expand in culture. The absence of significant 
lysis of CD56+CD56CAR+ T cells by bulk CD56CAR+ T cells shows 
that CD56CAR+ T cells do not kill themselves and are therefore 
evading autolysis. The absence of an increased IFN-γ response 
in either the CD4+ or CD8+ populations of CD56CAR+ T cells in 
the presence of CD56+CD56CAR+ T cells strongly suggests that 
CD56CAR+ T cells are not activated by CD56+CD56CAR+ T cells. In 
sum these data infer that CD56CAR+ T cells evade fratricide due 
to a lack of activation in response to autologous CD56+CD56CAR+ 
T cells. 
Our aAPC co-culture system of expansion of CAR+ T cells 
results in high percentages of CD56+ T cells at the end of a 28 
day culture period. Losing this population of cells due to 
fratricide in the culture could significantly diminish 
expansion kinetics of CAR+ T cells impeding translation of 
these T cells to the clinic for therapeutic use. Maintenance 
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of expansion kinetics in CD56CAR+ T cells as compared to 
CD19CAR+ T cells highlights that co-expression of the CD56 
antigen and the CD56-specific CAR is not hindering the ability 
to expand out clinically relevant numbers of CAR+ T cells.  
 There are two sources of CD56+ T cells in the culture. 
CD56 negative T cells proliferate in response to activation 
and can generate CD56+ T cells and CD56+ T cells can 
proliferate producing more CD56+ T cells. Similar expansion 
kinetics of the CD56 negative and CD56+ fractions of CD19CAR+ 
and CD56CAR+ T cells as well as similar generation and 
maintenance of CD56 antigen expression in these fractions 
demonstrates that both sources of obtaining CD56+ T cells are 
functioning in CD56CAR+ T cells. The expansion and maintenance 
of CD56+ T cells in the culture could be advantageous in 
reference to targeting tumors since CD56+ T cells are 
associated with enhanced effector potential and MHC 
unrestricted cytotoxicity.  
 While other CARs have been generated with specificity to 
T cell expressed TAAs, the ability of CD56+CD56CAR+ T cells to 
evade fratricide is to our knowledge a unique observation. 
CD30 expression on CD30CAR+ T cells is only expressed by low 
percentages of cells [21] inferring that self-targeting may be 
occurring in the culture although not demonstrated in bulk 
culture assays. CD38CAR+ T cells could not be generated unless 
cultured in the presence of CD38-specific antibody to prevent 
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self-targeting [18]. The ability of CD56+CD56CAR+ T cells to 
survive and expand in culture and to not result in IFN-γ 
production by bulk CD56CAR+ T cells infers that the CD56 
antigen on CD56CAR+ T cells is either not recognized by the 
CD56CAR or despite recognition is functionally beneficial to 
CD56CAR+ T cells in an unknown manner that allows for escape 
from autolysis.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88 
 
Chapter 4: Evaluating the mechanism of fratricide evasion by 
CD56-specific CAR+ T cells through investigating their CD56 
antigen 
4.1 Introduction: 
 The CD56 antigen is co-expressed on CD56CAR+ T cells 
despite the theoretical capacity to target self. Data from 
chapter 3 suggest that these CD56CAR+ T cells co-expressing the 
CD56 antigen do not undergo fratricide nor do they result in 
activation of autologous CD56CAR+ T cells. With this data in 
hand, we want to take a closer look at the CD56 antigen on 
these cells as compared to the CD56 antigen on CD19CAR+ T 
cells to determine if selective pressure of targeting self has 
resulted in antigen modifications to evade fratricide. Since 
the CD56 antigen has been shown to have signaling capacity in 
T cells [39] we also want to look for general protein 
expression differences between CD19CAR+ T cells and CD56CAR+ T 
cells to determine if activation of specific signaling 
networks could play a role in enabling CD56+CD56CAR+ T cells to 
survive despite self-recognition. 
 In this aim we demonstrate the loss of staining for the 
CD56 antigen on CD56CAR+ T cells with the mAb clone N901, the 
mAb from which the CD56CAR scFv was generated. Our data 
strongly suggest that loss of staining with N901 is not a 
result of epitope escape as the CD56 antigen on CD56CAR+ T 
cells is identical to that on CD19CAR+ T cells. We see 
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significant differences in the protein expression profile of 
CD56CAR+ T cells as compared to CD19CAR+ T cells inferring that 
fratricide escape could be a result of differential signaling 
events.  
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4.2 Results: 
4.2.1 Expression of the CD56 antigen on CD56CAR+ T cells; 
evaluating epitopes. 
 Weekly surface staining for the CD56 antigen was 
performed with the CD56-specific mAb clone B159. The location 
where this antibody binds is unknown. When following CD56 
expression on T cells in CD19CAR+ cultures as compared to 
CD56CAR+ cultures, both CAR+ cultures increased percent CD56 
expression as the culture progressed and this percent CD56 
expression was significantly different between CARs (Figure 
17A, p=0.0431, n=4)although significant differences were only 
seen at day 7 (p<0.0001, n=4). 
 Weekly surface staining for the CD56 antigen was also 
performed with the CD56 mAb corresponding to the CD56CAR scFv, 
clone N901. Following CD56 expression in CD19CAR+ T cells as 
compared to CD56CAR+ T cells demonstrates a significant 
difference (Figure 17A,p=0.0002, n=4) in the percent CD56 in 
the CAR+ cultures over time. CD56CAR+ T cells began to 
significantly lose CD56 expression when evaluated with clone 
N901 after only 7 days of co-culture (p<0.0001, n=4).  
 When comparing percent CD56 expression with the two 
varying mAbs within the same culture of CAR+ T cells, over time 
the N901 clone always stains a slightly greater percent CD56 
than the B159 clone reaching significance (p=0.0470, n=4, 
Figure 17B). With CD19CAR+ T cells the percent CD56 expression 
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over the culture remains fairly consistent and is not 
dependent on the mAb used as there is no significant 
difference in percent CD56 expression with the two varying 
mAbs, B159 and N901, at any specific time point (Figure 17B). 
CD56CAR+ T cells have significantly diminished ability to stain 
with the CD56 mAb clone N901 as compared to staining seen with 
the CD56 mAb clone B159 (p=0.0002, n=4) beginning at day 14 of 
co-culture (p<0.05, n=4). These data infer that the epitope 
where the mAb clone N901, and therefore the CD56CAR, binds is 
no longer detectable on CD56CAR+ T cells.  
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Figure 17: CD56 antigen expression on CD19CAR+ and CD56CAR+ T 
cells with various mAbs.  
Expression of CD56 antigen was followed over 28 days on 
CD19CAR+ and CD56CAR+ T cells with different CD56 specific mAb 
clones. (A) Percent CD56 expression as assessed by flow 
cytometry analysis (LEFT-Clone B159, RIGHT- Clone N901). 
(B)Overlay of the two CD56 specific mAb clones for each CAR 
over the culture period (LEFT-CD19CAR, RIGHT-CD56CAR). Data 
are shown as the mean and SEM of four donors. Statistical 
analysis was analyzed using RM two-way ANOVA with Bonferroni’s 
Multiple Comparison post-test. 
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4.2.2 Epitope loss through epitope escape 
 The three main isoforms of CD56 do not vary in the 
extracellular domain. Although the 120, 140 & 180 KDa isoforms 
of CD56 all have two F3 domains and five Ig modules, there are 
multiple locations for posttranscriptional modifications on 
the CD56 antigen including N-linked glycosylation and PSA 
expression. There are also three regions where alternative 
splicing could contribute to extracellular variations 
[24,25,26,29,30,75]. Beyond the known conserved regions for 
extracellular modifications there are many CD56 variants that 
result from mutations or minor sequence variations.  
 Positive staining for the CD56 antigen with the B159 mAb 
confirms surface expression of the CD56 antigen on CD56CAR+ T 
cells. Combined with the inability of CD56CAR+ T cells to be 
activated by CD56+CD56CAR+ T cells, the loss of staining with 
the N901 mAb for CD56 by these CD56+CD56CAR+ T cells suggests 
that the CD56 antigen either no longer expresses the epitope 
where the N901 mAb binds, the epitope where the CD56CAR binds, 
or this epitope is no longer recognized. One possible cause of 
loss of epitope staining could be a result of epitope escape. 
There are multiple routes through which epitope escape could 
be achieved including modifications in PSA expression, 
modifications of N-linked glycosylation expression, 
alternative splicing and/or mutations.  
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4.2.2.1 Polysialic acid modifications of CD56 
 To investigate if PSA could contribute to loss of N901 
staining we evaluated the ability of a highly polysialiated 
tumor cell line, CHLA-255, to stain with the mAb clones B159 
and N901 before and after PSA removal. Endoneuraminidase-N 
(Endo-N) is a PSA specific enzyme that results in the 
degradation of sialic acid polymers with α-2,8-linkage which 
is consistent with PSA attached to NCAM.   
 Prior to treatment with Endo-N CHLA-255 stain positive 
for PSA-CD56, B159 and N901 (Figure 18A). Four hours following 
Endo-N treatment CHLA-255 have diminished PSA-CD56 expression 
but do not have reduced B159 or N901 staining (Figure 18A). 
Since N901 binds the CD56 antigen with or without PSA on the 
CD56 antigen inferring that PSA is does not play a role in the 
binding of the mAb clone N901. To further confirm these 
results this PSA removal study was repeated in the 
artificially generated tCD56+ K562 Parentals, the tumor cell 
line used as a positive control for CD56CAR redirected lysis. 
Upon staining these cells with PSA-CD56 and seeing no 
staining, we concluded that these tCD56+ K562 parentals do not 
express PSA on their CD56 antigen (Figure 18B). These tCD56+ 
K562 parentals still retained staining with both the B159 and 
N901 mAbs for CD56 even though they do not express PSA (Figure 
18B). These data confirm that PSA expression on the CD56 
antigen does not impact the binding of N901 to the CD56 
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antigen and therefore strongly suggest that loss of N901 
staining by the CD56 antigen on CD56CAR+ T cells is not a 
result of PSA modifications. 
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Figure 18: The effect of PSA removal on CD56-specific mAb 
staining. Cell lines (A) CHLA-255 and (B) CD56+ K562 Parentals 
were stained for CD56 antigen expression with different CD56 
specific mAb clones including a PSA-specific CD56 antibody 
prior to treatment (LEFT) and four hours following treatment 
with Endoneuraminidase-N (RIGHT, enzyme for PSA removal).  
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4.2.2.2 N-linked glycosylation modifications of CD56 
 There are six N-linked glycosylation sites on the CD56 
antigen [24,25,26,29,30,75]. To evaluate if N-linked 
glycosylation modifications are impacting the ability of the 
N901 mAb to recognize the CD56 antigen on CD56CAR+ T cells we 
generated truncated CD56 N-linked glycosylation mutants. 
Mutants were generated by replacing N-linked glycosylation 
sites, asparagine codons (AAG) to glutamine codons (CAG). Each 
N-linked glycosylation site was mutated individually 
generating mutants N1-N6 corresponding to the mutated 
glycosylation site with N0 being the non-mutated tCD56 
control. 
 These mutants were expressed in K562 Parentals, which do 
not naturally express CD56, through SB electrotransfer. If the 
glycosylation at one of these sites is responsible for the 
binding of the N901 mAb then it is expected that it will stain 
positive for the CD56 antigen with the B159 mAb but will not 
stain with the N901 mAb (Figure 19A). A No DNA electroporation 
control demonstrates that K562 Parentals do not express the 
CD56 antigen irrespective of the mAb used for staining. N0K562 
Parentals stain positive with both B159 and N901 mAbs 
demonstrating the expression of the epitopes necessary for the 
binding of both mAbs by the non-mutated tCD56 (Figure 19B). 
Each individual N-linked glycosylation mutant stained positive 
for both B159 and N901 mAbs (Figure 19C). The inability of 
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these N-linked glycosylation mutations to result in diminished 
CD56 expression as assessed with N901 staining demonstrates 
that no individual N-linked glycosylation site or the 
resulting glycosylation is responsible for the binding of the 
N901 mAb to the CD56 antigen. These data strongly suggest that 
N-linked glycosylation is not causing the loss of N901 
staining of the CD56 antigen on CD56CAR+ T cells.  
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Figure 19: The impact of N-linked glycosylation mutations on 
CD56-specific mAb staining. K562 Parentals were stained for 
CD56 antigen expression with different CD56 specific mAb 
clones including a PSA-specific CD56 antibody prior to 
treatment (LEFT) and four hours following treatment with 
Endoneuraminidase-N (RIGHT, enzyme for PSA removal).  
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4.2.2.3 Mutations and alternative splicing of CD56 
 The CD56 antigen has three conserved regions for sequence 
variation including the VASE domain, MSD1 region and AAG 
insert [24,25,26,29,30,75]. In order to determine if 
alternative splicing, mutations or deletions within the CD56 
antigen result in loss of N901 epitope recognition in CD56CAR+ 
T cells the sequence of CD56 mRNA from CD19CAR+ T cells was 
compared to sequence of the mRNA from CD56CAR+ T cells. Using 
two different primer sets to generate cDNA the expression of 
all three isoforms was accounted for [76]. The R1 sequence 
data corresponds to the cDNA from the PCR for the 120kDa 
isoform of CD56 while the R2 sequence data corresponds to the 
cDNA from the PCR for the 140 and 180kDa isoforms of CD56. The 
R1 sequence data was aligned to reference sequences for CD56 
(best matching NM_001242608) and a consensus sequence for the 
CD19CAR and CD56CAR was generated (Figure 20A, APPENDIX A)and 
translated (APPENDIX B). Upon aligning these two consensus 
sequences no differences were detected between the CD56 
antigen on CD19CAR+ T cells as compared to that on CD56CAR+ T 
cells (Figure 21A). This process was repeated for the R2 cDNA 
except it best matched NM_001242607 (Figure 20B) and the 
consensus sequence was generated (APPENDIX C) and translated 
(APPENDIX D). There were no sequence differences detectable 
between the CD56 mRNA from CD19CAR+ T cells as compared to the 
CD56 mRNA from CD56CAR+ T cells for the 140 and 180kDa isoforms 
 104 
 
of CD56 (Figure 21B). These results demonstrated that our CAR+ 
T cells express the 120 kDa isoform of the CD56 antigen and 
suggest they express both the 140 and 180 kDa isoforms of the 
CD56 antigen, although due to the nature of Next-generation 
sequencing the 140kDa reads cannot be separated from those for 
the 180kDa isoform. To our knowledge this is the first time 
the 120 or 180 kDa isoforms of the CD56 antigen has been 
described for expression on T cells.  
The sequencing data revealed a missing amino acid 
(skipped exon), AAG, in both the R1 and R2 analyses (Figure 
21A&B). In the 120kDa isoform aa 599-600 are changed from QG 
to just R and in the 140/180kDa isoforms this occurs at aa 
635-636. We hypothesize that this exon is the AAG insert that 
can be optionally included in the CD56 protein sequence. In 
sum these data demonstrate the mRNA sequence of CD19CAR+ T 
cells to be identical to that of CD56CAR+ T cells. Since the 
Cd56 antigen on CD19CAR+ T cells is still recognized by both 
CD56 mAbs it is unlikely that loss of epitope recognition on 
the CD56 antigen expressed by CD56CAR+ T cells is a result of 
alternative splicing or mutations of the CD56 antigen. These 
data strongly suggest that diminished binding of the N901 mAb 
to the CD56 antigen on CD56CAR+ T cells is not a result of 
sequence modifications to the CD56 antigen expressed on these 
cells. 
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Figure 20: Next-Generation Sequencing reads coverage spanning 
the coding sequences.  
The consensus sequences from CD19CAR and CD56CAR samples were 
aligned to all known CD56 RefSeq sequences and the most 
closely matched transcript (NM_001242608 for R1, NM_001242607 
for R2) are shown. Consensus sequences (A) R1 aligned to 
NM_001242608 and (B) R2 aligned to NM_001242607. The coverage 
or sequencing depth spanning the CD56 coding sequence 
(the green wiggle graph)is shown. On average more than 10,000x  
The coverage (on average more than 10,000x) is similar between 
the CD19CAR and CD56CAR demonstrating no bias in sampling 
during sequencing. The bottom panel (yellow bars) is the 
coding sequence (CDS) and grey arrows are the exons. Analysis 
was performed by Dr. Sonny Ang.  
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Figure 21: Comparison of consensus sequences from CD19CAR and 
CD56CAR CD56 antigen transcripts.  
Consensus sequences (A) R1 aligned to NM_001242608 and (B) R2 
aligned to NM_001242607 for the CD19CAR and CD56CAR were 
aligned with each other. The sequences were analyzed for 
differences. All sequences showed a skipped exon (AAG) in the 
bottom panel. Figure illustrates that there is no difference 
in CD56 transcript (R1 or R2) between the CARs. Analysis was 
performed by Dr. Sonny Ang. 
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4.2.3 Protein expression profile of CD56CAR+ T cells 
 CD56 has been shown to have signaling capacity in neurons 
[24,25,26,28,29,33,75] as well as in T cells [39]. The ability 
of CD56 signaling to synergize with that achieved through CD3 
in T cells could impact the survival of CD56+ T cells. To 
evaluate the possibility that differential signaling and the 
resulting protein expression could play a role in the survival 
mechanism of CD56+CD56CAR+ T cells we compared the protein 
expression profile of CD56CAR+ T cells to that of CD19CAR+ T 
cells through RPPA. 
 Median centered unsupervised hierarchical clustering of 
the protein expression data resulted in a significant 
difference (p<0.05) in the fractionation of CD19CAR+ T cells 
versus CD56CAR+ T cells (Figure 22). These data demonstrate a 
significant difference in the protein expression profile of 
CD56CAR+ T cells as compared to CD19CAR+ T cells. Two clusters 
of proteins with the greatest expression variation between the 
two CARs were investigated in further detail for functional 
implications. Cluster 1 proteins include Gab2, Cyclin B1, 
CDK1, FoxM1, Chk1, Rb(pS807), TFRC, eIF4G and STAT5 alpha and 
have higher expression in CD56CAR+ T cells as compared to lower 
expression in CD19CAR+ T cells. Cluster 2 proteins include 
VEGFR2, GSK3 alpha/beta, MAPK (pT202), Src (pS235) and YB-1 
(pS102) which have lower expression in CD56CAR+ T cells as 
compared to higher in CD19CAR+ T cells (Table 3). These 
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proteins were then linked to signaling pathways that they play 
roles in using WikiPathways database (Table 4). Many of the 
proteins within the two clusters play roles in TCR signaling, 
NCAM (CD56) signaling, cell cycle signaling and cell motility 
signaling pathways. These combined data demonstrate protein 
expression profile differences between the two different CAR+ T 
cells that could be due to multiple causes from differential 
CAR signaling strength to being responsible for fratricide 
escape.  
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Figure 22: Median centered unsupervised hierarchical 
clustering of the protein expression of CD19CAR+ and CD56CAR+ T 
cells. Protein levels depicted in a heatmap with green 
indicating lower values and red higher values. The samples 
were normalized to protein loading, log2 transformed and 
median centered log2 for unsupervised hierarchical clustering. 
Two clusters of proteins with high levels of variation are 
zoomed in on for more detailed analysis. The heatmap was 
generated using Cluster 3.0 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm), 
by the MDACC’s Cancer Center Support Grant (CCGS) Reverse 
Phase Proteomic Array (RPPA) Core Facility. This data is from 
four donors matched for each CAR. 
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Cluster 1 
Proteins
Cluster 2 
Proteins
Gab2 VEGFR2
Cyclin B1 GSK3 
alpha/beta
CDK1 MAPK (pT202)
FoxM1 Src (pY416)
Chk1 S6 (pS235)
Rb (pS807) YB-1 (pS102)
TFRC
eIF4G
STAT5 α
CD19CAR+
CD56CAR+
A
B
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Table 3: Clustering of the proteins with greatest differential 
expression between CD19CAR+ and CD56CAR+ T cells. Some of the 
(A)List of proteins from the two clusters of proteins with 
high levels of variation are listed in (LEFT) cluster 1 
(RIGHT) cluster 2. (B)Indication of increased or decreased 
expression of (LEFT) cluster 1 and (RIGHT) cluster 2 proteins 
in CD19CAR+ and CD56CAR+ T cells as compared to the median.  
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AGE/RAGE x x x
Alpha 6 Beta 4 signaling x x
Angiogenesis x x x
Arylhydrocarbon receptor (AhR) 
signaling x x
ATM Signaling x x x
BDNF signaling x x x x
Cell Cycle Checkpoints x x x
EGF/EGFR Signaling x x x x
EPO Receptor Signaling x x x
ErbB Signaling x x x x
Focal Adhesion x x
GPCR downstream signaling x x
IL-2 Signaling x x x x
IL-3 Signaling x x x x
IL-4 Signaling x x x
IL-5 Signaling x x x
IL-7 Signaling x x
IL-9 Signaling x x
Insulin Signaling x x x x
Interferon type I signalings x x
JAK/STAT x x x
Kit receptor signaling x x x x
L1CAM interactions x x
Leptin signaling x x
Mitotic G1-G1/S phases x x x
NCAM signaling for neurite out-growth x x
NGF signalling via TRKA from the plasma 
membrane x x x x
Notch Signaling x x x
Oncostatin M Signaling x x
Processing of Capped Intron-Containing 
Pre-mRNA x x
Prolactin Signaling x x x x
Regulation of Microtubule Cytoskeleton x x
Regulation of toll-like receptor 
signaling x x
TCR Signaling x x
TSLP Signaling x x x x
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Table 4: Correlation of cluster proteins with signaling pathways. 
Clustered proteins were run through WikiPathways database 
(http://www.wikipathways.org)and resulting pathways were 
broken down, linked, and integrated into a table of shared 
pathway interactions. Data analysis was performed by Dr. Sonny 
Ang. 
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4.3 Discussion: 
 In this aim we demonstrated that although CD56CAR+ T 
cells co-express the CD56 antigen, as determined by cell 
surface staining with the CD56mAb B159, that the CD56antigen 
that they express has significantly diminished recognition by 
the CD56 mAb N901, which corresponds to the specificity of the 
CD56CAR. Our data strongly suggest that loss of this epitope 
recognition by cell surface staining is not a result of 
epitope escape. This conclusion is supported by the fact that 
PSA removal and N-linked glycosylation mutations did not 
recapitulate this diminished N901 staining in control cell 
lines, which instead maintained staining for the CD56 Ag with 
both CD56 mAb clones N901 and B159. Sequencing of the mRNA 
coding for the CD56 antigen on CD56CAR+ T cells and comparing 
it to the sequence obtained from CD56 mRNA in CD19CAR+ T cells 
did into present any differences. These data infer that the 
CD56 antigen on CD56CAR+ T cells is not different than that 
expressed on CD19CAR+ T cells, which stain with both Cd56 mAbs, 
meaning that this loss of epitope recognition by the N901 CD56 
mAb is not a result of epitope escape. Our data does however 
show a significant difference in the protein expression 
profile of CD19CAR+ T cells as compared to CD56CAR+ T cells. 
These protein differences could represent an intrinsic 
mechanism used by CD56+CD56CAR+ T cells to evade fratricide.  
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 An antigen losing the ability to be recognized by a 
specific mAb, loss of epitope recognition, could be a result 
of epitope escape (irreversible loss of epitope) or epitope 
masking (reversible blockade of the epitope). Epitope escape 
of an antigen would demonstrate a weakness in using this TAA 
as a target. If the antigen is prone to modifications, 
mutations or alternative splicing that allow it to escape 
targeting this would give the tumor a route to escape from 
being targeted by the therapy. Epitope masking could be 
concerning as well depending on the factor causing the masking 
and the availability of this factor to the tumor cells. We 
hypothesize that epitope masking is the cause of this loss of 
epitope recognition and that it is a result of CD56CAR being 
bound to the CD56 antigen in cis on CD56+CD56CAR+ T cells. 
 Epitope masking due to cis interactions of the CD56 
antigen with the CD56CAR raises a multitude of questions that 
future studies could investigate. For example, would this cis 
interaction activate downstream signaling through the CD56 
antigen and/or the CD56CAR? Could a cis interaction cause CAR 
activation? Is it possible for a T cell to literally kill 
itself? We know that T cells can kill other T cells [22] and 
that they are somehow protected from their own killing 
machinery [74] so is killing of self on a single cell level 
possible? Answering these questions could shed light on T cell 
biology that to my knowledge has not been investigated.  
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 Protein expression differences between CD56CAR+ and 
CD19CAR+ T cells could be a result of CD56 and CD56CAR cis 
interactions or could merely be a result of differences in the 
strength of signaling achieved through the two different CARs 
since the affinity of each CAR for its target antigen varies 
based upon the scFv used to generate the CAR. Many of the 
proteins with significant differential expression play roles 
in TCR signaling, NCAM (CD56) signaling, cell cycle signaling 
and cell motility signaling pathways. Also several of these 
proteins are linked in pathways. For example T cell activation 
leads to the up-regulation of the transferrin receptor (TFRC) 
which stimulates cell proliferation [77]. Actively 
proliferating cells express the transcription factor FoxM1 
(forkhead box M1)  [78] and FoxM1 can cause increases in the 
expression of cyclin B1  [79] which needs CDK1 (cyclin-
dependent kinase 1) expression to function [80]. T cell 
activation also leads to the activation of the production of 
cytokines such as IL-2 which when it engages it’s receptor 
(CD25) initiates STAT5 (signal transducer and activator of 
transcription) signaling [81] and also activates Gab2 (Grb2-
associated binder-2) [82], both of which mediate signaling 
downstream of IL-2 [81,82].  These are all proteins that have 
higher expression in CD56CAR+ T cells as compared to CD19CAR+ T 
cells and could correlate to differential signaling or 
different strength of activation achieved through the CARs. We 
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demonstrate that CD56CAR+ T cells produce significant levels of 
IL-2 in response to antigen stimulation which would account 
for a significant portion of the cluster 1 proteins being 
expressed at higher levels. 
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CHAPTER 5: General Discussion & Future Directions 
5.1 Dissertation Summary 
 Through these thesis studies we have generated and 
expanded CD56-specific CAR+ T cells. These cells have 
demonstrated in vitro functions including cytokine production 
in response to CD56 antigen on target cells as well as the 
ability to lyse CD56 antigen expressing targets whether 
autologous or allogeneic in a CAR-specific manner. When tested 
in vivo CD56CAR+ T cells significantly enhanced overall 
survival of the mice and delayed tumor growth in both “low” 
and “high” tumor burden models. Despite the expression of the 
CD56-specific CAR, a subset of CD56CAR+ T cells co-expressed 
the CD56 antigen on their cell surface and did not demonstrate 
the ability to target each other, undergo fratricide, or show 
signs of activation in the presence of each other. When 
further evaluating the ability of CD56CAR+ T cells co-
expressing the CD56 antigen to evade fratricide we 
demonstrated that the CD56 antigen they expressed no longer 
stained with the CD56 specific N901 mAb clone, which 
corresponds to the specificity of the CD56CAR, although it 
still stains positive for the CD56 antigen with the CD56 
specific mAb B159. Based on this lost ability to stain with 
the N901 epitope we investigated whether the CD56 antigen had 
undergone epitope escape. Our data looking at PSA 
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modifications, N-linked glycosylation mutants and at the mRNA 
sequence did not indicate any route for epitope escape. Our 
data do however show a significant difference in the protein 
expression profile of CD56CAR+ T cells as compared to CD19CAR+ 
T cells. Although our data are inconclusive towards the 
mechanism of fratricide escape utilized by CD56+CD56CAR+ T 
cells our study does generate some questions about the role 
the CD56 antigen plays in T cells and has generated functional 
CD56CAR+ T cells that show clinical potential.  
5.2 Clinical Relevance 
 CD56 is stably expressed on a wide range of tumors 
including both hematological and solid tumors[20]. Due to the 
nature of CAR design, this one CAR can be applied to any CD56 
positive malignancy for any patient without modifications 
since CAR specificity is achieved irrespective of MHC 
restrictions. There are some considerations future studies 
should take when moving CD56CAR+ T cells into the clinic 
including improving upon the CAR design with various co-
stimulatory molecules or the addition of co-stimulatory 
molecules, i.e. third generation CARs, safety measures, and 
using the CD56CAR in combination with other available 
therapies. 
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5.2.1 Safety Measures 
 Although CD56 is highly and stably expressed by a wide 
range of malignancies, this antigen is also expressed on 
normal tissues including the central and peripheral nervous 
system, neuroendocrine glands, cardiomyocytes and NK cells 
[20]. Clinical trials have targeted CD56 with systemic 
treatments, immunotoxin conjugated mAbs such as anti-NCAM-
mayatansine immunotoxin (huN901-DM1) [20,52], and loco-
regional treatments, with T cells and bispecific CD3/CD56 
antibodies [20,66], and have demonstrated safety and efficacy. 
Despite these promising results precautions need to be taken 
to avoid “on target/off tumor” related toxicities [4]. “The 
good news-and the bad news-is that the immune system is 
incredibly powerful” as Robert Tepper puts it [83]. CAR based 
immunotherapies can be very effective and sometimes too 
effective. There have been several attempts to target antigens 
expressed on normal tissues as well as malignant tissues which 
have resulted in deaths and severe toxicities as it does not 
take long for the T cells to do more damage than the cancer.  
GD2-specific T cells did not generate toxicities in 
clinical trials although expressed on normal tissues and 
despite some toxicity/pain issues with anti-GD2 antibody based 
therapies [64,65,84,85]. Anti-CD56 antibody based studies, 
specifically with the N901 clone used to generate the CD56-
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specific CAR have not demonstrated significant off target 
effects in clinical trials [20,52]. Despite these promising 
results “on target/off tumor” side effects of targeting a TAA 
also expressed on normal tissues have to be approached with 
caution as previous studies of such CARs has demonstrated 
[2,4,13,16,62,86,87]. Although not addressed in these studies, 
safety measures would be necessary for clinical application of 
CD56-specific T CAR+ T cells since the CD56 antigen is also on 
normal tissues. CD56-specific T cells have successfully been 
generated that co-express HyTK (hygromycin thymidine kinase) 
which functions as a suicide gene for elimination in the case 
of deleterious off target effects [4,13,16,62]. TK converts 
ganciclovir (GCV) into a toxic drug leading to conditional 
ablation metabolizes [18F]FEAU as a tracer for positron 
emission topography (PET). We were able to expand CD56CAR+ T 
cells co-expressing HyTK (Figure 23A, demonstrate function of 
the TK to uptake the PET imaging tracer (Fig 23B) and the 
ability to conditionally ablate the HyTK positive T cells upon 
addition of ganciclovir (Fig 23C). These combined data 
demonstrate our ability to produce clinical grade CD56RCAR+ T 
cells with not only imaging capacity but conditional ablation 
in case of off-target effects. There are other safety measures 
available including the expression of inducible caspase 9 as 
an inducible suicide gene [88] or expression of the CAR as 
mRNA limiting CAR expression to a couple of days [89]. 
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Figure 23: Assessment of expression and function of co-
transfected fusion gene HyTK for imaging and conditional 
ablation of CAR+ T cells.  
(A) Percent expression of HyTK on CD56CAR+ T cells as measured 
by flow cytometry (Top panel-No DNA control; Bottom panel- 
CD56CAR+HyTK+ T cells. (B) In vitro assay to evaluate ability 
of TK to metabolize the PET tracer used for imaging. (C) In 
vitro assay to evaluate ability of TK to convert Ganciclovir 
into a toxic drug leading to cell death. 
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5.2.2 Combination Therapy 
 Although CAR based immunotherapies have shown efficacy 
against CD19+ and GD2+ malignancies, there are improvements 
that can be made to improve upon the success of CARs in the 
clinic. Beyond improving CARs through the use of different or 
additional co-stimulatory molecules, which is one direction 
the field is going, it could be advantageous to combine CAR 
with other available therapies.  
 The use of blocking antibodies for CTLA-4 and PD-1 
[90,91] could help to enhance CAR-mediated responses. 
Preventing the activation of these inhibitory receptors would 
potentially enable a stronger and longer lasting CAR mediated 
anti-tumor response. This blockade could also impact the 
activation and recruitment of surrounding immune cells aiding 
in the anti-tumor response. One large hurdle for CAR-based 
immunotherapies is in vivo persistence. Even though CAR+ T 
cells mediate anti-tumor responses, if they do not survive in 
the patient they will not impart protection against relapse. 
Cytokine support, such as IL-15 administration or membrane 
bound expression, has demonstrated the capacity to improve in 
vivo persistence of CAR+ T cells in mice [92] and have the 
potential to improve CAR-based immunotherapies in the clinic.  
 One concern with targeting almost any tumor expressed 
antigen is the potential for antigen escape. The tumor cells 
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could potentially down-regulate or modify the target antigen 
rendering the therapy ineffective. The use of two CARs 
simultaneously against different targets could potentially 
prevent antigen escape as well as generate a stronger anti-
tumor response [13,93]. This strategy also accounts for tumor 
heterogeneity. I have only discussed a few of the many 
possibilities for therapies that could be combined with CARs 
[13] that could greatly impact efficacy in the clinic.  
5.3 Fratricide escape as a result of in vitro culture. 
 T cells are capable of killing T cells (fratricide)[22] 
but it is hypothesized that killing is a directional process 
whereby the killer cell is protected [74]. We have confirmed 
the ability of T cells to kill T cells through autologous CRAs 
where CD56CAR+ T cells lyse CD56+ T cells with or without the 
CD19CAR. Despite this capacity for T cells to lyse T cells, 
CD56CAR+ T cells do not kill CD56+CD56CAR+ T cells. Not only do 
CD56CAR+ T cells not significantly lyse CD56+CD56CAR+ T cells, 
they do not produce significant IFN-γ, up-regulate CD69 (a 
marker of activation) or express CD107a (a marker for 
degranulation). These data demonstrate that CD56CAR+ T cells do 
not perform fratricide on other CD56CAR+ T cells expressing 
CD56 and infer that they are not even activated by them. 
 We wanted to test if this evasion of fratricide by 
CD56+CD56CAR+ T cells was an artifact of the cells being 
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cultured together or only seen within a donor. Using bulk 
CD56CAR+ T cells as the effectors from four donors (labeled 
with A-D) we set up a CRA where bulk CD19CAR+ T cells and 
CD56CAR+ cells (which consists of CD56neg and CD56+ CAR+ T 
cells) from the same four donors were targets. If fratricide 
evasion is indeed an artifact generated from being cultured in 
the same flask or a within donor phenomenon it would be 
expected that CD56CAR+ T cells from one donor could lyse 
CD56+CD56CAR+ T cells from another donor. If these factors do 
not play a role in fratricide escape it is expected that 
CD56+CD56CAR+ T cells will evade targeted irrespective of the 
effector. CD56CAR+ T cells from all four donors significantly 
lysed CD56+ K562 Parentals (positive control, p<0.0001, n=4) as 
well as bulk CD19CAR+ T cells (p<0.0001, n=4) from all donors 
as expected, while not significantly lysing K562 Parentals or 
Nalm-6 (negative control targets). Irrespective of 
donor/culture, CD56CAR+ T cells did not significantly lyse any 
of the bulk CD56CAR+ T cells (Figure 24). These data 
demonstrate that this evasion of fratricide by CD56+CD56CAR+ T 
cells is not a within donor or flask phenomenon. This does not 
eliminate the possibility that something within our in vitro 
system of culturing could be contributing to this phenomenon.  
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Figure 24: Fratricide escape across donors and in response to 
targeting by CD56CAR+ T cells.  
Redirected specificity of CD56CAR+ T cells against bulk 
CD19CAR+ and CD56CAR+ targets at day 35 assessed by a 4 hour 
CRA at a 20:1 E:T ratio. Targets are from four different 
donors corresponding to the four donors used as effectors.  
Results of specific lysis are expressed as mean ± SEM of four 
donors. Significance analyzed using one-way ANOVA with 
Bonferroni’s Multiple Comparison post-test.  
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5.4 Epitope escape in tumor cells. 
 The diminished ability of the CD56 antigen on CD56CAR+ T 
cells to stain for CD56 with the N901 mAb for the CD56 antigen 
infers that the epitope where this mAb binds has been lost. 
The epitope where N901 binds is the same as where the CD56CAR 
binds. In order for the CD56CAR to be a viable immunotherapy 
it is important that the antigen is not undergoing epitope 
escape. Epitope escape of the antigen of T cells would infer 
that tumor cells could respond to CD56 targeting in the same 
manner. Our data strongly suggest that the loss of binding of 
the CD56 antigen by the N901 mAb is not due to epitope escape. 
PSA removal and N-linked glycosylation mutations did nto 
recapitulate this loss of staining. Sequencing of the mRNA for 
the CD56 antigen in CD56CAR+ T cells, which has diminished N901 
binding, did not reveal any differences in sequence as 
compared to the mRNA for the CD56 antigen in CD19CAR+ T cells, 
which retain N901 binding.  
 To further investigate the ability of tumor cells to 
undergo epitope escape in response to CD56CAR targeting, we 
performed in vitro tumor versus T cell co-culture experiments. 
We performed these experiments in the presence of exogenous 
IL-2 and IL-21 with either continuous T cell challenge, 
meaning T cells were added and left with the tumor (CHLA-255) 
for a week, or with 24 hour challenges, meaning the T cells 
 133 
 
were added to the tumor for 24 hours and then washed away 
(Figure 25A). The T cells were added at various tumor to T 
cell ratios (2:1, 4:1 and 8:1). In the two highest T cell 
ratios (2:1 and 4:1) the tumor cells did not survive in either 
the continuous or 24 hour challenges. In the lowest T cell 
ratio (8:1) a very small number of tumor cells survived. We 
were able to perform one 7 day challenge and then let the 
tumor cells recover without challenge for 19 days before we 
had enough cells to analyze. We were able to perform two 24 
hour challenges with a 3 day rest in-between challenges and 
due to the low number of surviving tumor cells they were 
allowed to rest 21 days to obtain enough cells for analysis. 
The initial analysis of CD56 expression on the tumor cells 
before being challenged with CD56CAR+ T cells demonstrated 
approximately 100% expression of the CD56 antigen with both 
CD56-specific mAb clones B159 and N901 (Figure 25B). Following 
the T cell challenges and the days of rest for tumor expansion 
the tumor cells did not demonstrate loss of B159 (Figure 25C) 
or N901 (Figure 25D) staining for the CD56 antigen in response 
to either type of T cell challenge. The ability of the CD56CAR+ 
T cells to kill all tumor cells in the co-culture in the two 
higher ratios and to diminish the number of tumor cells in the 
lowest ratio without resulting in tumor cells with epitope 
escape infers that epitope escape of the tumor cells is not 
likely. This study was only performed on CHLA-255, a 
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neuroblastoma cell line and it is possible that different 
tumors are more capable of epitope escape than others. Future 
experiments evaluating epitope escape by tumor cells in 
response to in vivo challenge with CD56CAR+ T cells are needed 
as they would more closely mimic the tumor behavior. 
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Figure 25: Evaluating antigen escape by tumor cells in 
response to CD56CAR+ T cell challenge.  
(A)Schematic describing the experimental design for the tumor 
and T cell co-culture experiments. (B) CD56 expression on 
tumor cells at day -2 prior to T cell challenge as assessed by 
flow cytometry analysis with CD56 mAbs B159 and N901. CD56 
expression on rested tumor cells (19 and 21 days) following T 
cell challenges at a 8 tumor cells to 1 T cell (8:1) ratio 
(two 24hr challenges or one 7 day challenge) as assessed by 
flow cytometry analysis with CD56 mAbs (C) B159 and (D) N901. 
Data shown are one representative donor of three.  
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5.5 Signaling differences between CD19CAR+ and CD56CAR+ T 
cells. 
 Our data demonstrate a significant difference between the 
protein expression profiles of CD19CAR+ T cells as compared to 
CD56CAR+ T cells. The proteins with the greatest differences 
showed links to cell cycle, TCR, and CD56 signaling pathways. 
Although this information is not conclusive and cannot be 
directly linked to the ability of fratricide escape of CD56CAR+ 
T cells, it does lead to several different hypotheses as to 
why these differences are present. It is possible that the two 
CARs signal with different strengths, that the CD56CAR has 
activated CD56 signaling in CD56CAR+ T cells or that it is a 
result of CAR and CD56 signaling synergy. Future studies need 
to be done to shed light on the impact these differences in 
protein expression have on the cells and in evaluating whether 
they are survival related, CD56 related, CAR related or all 
three. Future studies investigating the contribution of CD56 
signaling to these pathways could progress the understanding 
of the role the CD56 antigen plays in T cells. 
5.6 Working model for fratricide escape by CD56+CD56CAR+ T 
cells. 
 Our studies have demonstrated that CD56CAR+ T cells do not 
kill or show signs of activation (up-regulation of IFN-γ, 
CD107a and CD69 expression)in response to CD56 antigen on 
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CD56CAR+ T cells although they do kill and show signs of 
activation in the presence of other CD56+ targets (autologous 
or allogeneic) that do not co-express that CD56CAR. The 
ability of targets expressing the CD56 antigen alone being 
capable to being lysed infers that even if the interaction of 
the CD56CAR activates CD56 signaling in the target cell, that 
this signaling alone is not enough for survival. The ability 
of CD56CAR expressing cells to be targeted by CD19CAR+ T cells 
when tCD19 antigen is artificially expressed on the cell 
surface infers that this ability of CD56CAR+ T cells to evade 
fratricide is not a cell specific ability or a result of 
internal signaling or protein expression.  
 With the combined data, we hypothesize that CD56CAR+ T 
cells co-expressing the CD56 antigen have all of their CD56 
antigen (at the N901 epitope) bound up by the CD56CAR due to 
cis interactions (Figure 26A). Cis interactions between the 
CD56CAR and CD56 antigen could explain the loss of surface 
staining with the N901 mAb. This higher expression of CAR than 
the CD56 antigen would result in the N901 epitope on the CD56 
antigen being tied up by interactions with CAR on its own cell 
surface resulting in minimal, if any, CD56 antigen and CD56CAR 
interactions in trans. The lack of trans interactions could 
explain why there is not significant lysis or IFN-γ production 
by CD56CAR+ T cells in response to CD56+CD56CAR+ T cells 
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(Figure 26B). To lose N901 staining while maintaining the 
functional targeting capacity of the CD56CAR on CD56+CD56CAR+ T 
cells (both of which our data demonstrate to be true) the 
ratio of CAR expression must be greater than CD56 antigen 
expression so that free CAR is still available for trans 
interactions and targeting of CD19CAR+ T cells (Figure 26C) as 
well as CD56+ tumor cells (Figure 26D). We hypothesize that 
this cis interaction between the CD56CAR and the CD56 antigen 
does not result in CAR activation or signaling but does result 
in CD56 signaling accounting for the differences in the 
protein expression profiles of CD56CAR+ T cells as compared to 
that of CD19CAR+ T cells.  
This hypothesis is supported by studies performed with 
other T cell antigen specific CARs. CD30 and CD44v6 are both T 
cell expressed antigens [94,95], but they are only expressed 
at low levels in T cells and CD30CAR+ and CD44v6CAR+ T cells 
are reported to not result in fratricide [19,21]. CD38 is a T 
cell expressed antigen that is highly expressed on activated T 
cells [71] and CD38CAR+ T cells are reported to undergo 
fratricide or autolysis [18]. Also our inability to generate 
tCD19+CD19CAR+ T cells could be a result of high level of tCD19 
expression that results from hygromycin selection. We have 
performed preliminary studies with a CD45-specific CAR and 
were not able to expand CAR+ T cells (data not shown) and CD45 
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is a ubiquitously and highly expressed antigen on T cells 
[96]. The level of expression of the targeted antigen in 
relation to CAR expression may be the key to generating T 
cells specific for T cell expressed antigens. Future studies 
would need to be performed to test this hypothesis, one of 
which could be overexpression assays. 
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Figure 26: Working model for fratricide escape and targeting 
by CD56+CD56CAR+ T cells.  
(A)Schematic of (A) cis interactions between the CD56 antigen 
and the CD56CAR on the same cell (B) trans interactions 
between a CD56+CD56CAR+ T cell with another CD56+CD56CAR+ T cell 
(C) trans interactions between a CD56+CD56CAR+ T cell with a 
CD56+CD19CAR+ T cell and (D) trans interactions between a 
CD56+CD56CAR+ T cell with a CD56+ tumor cell and the resulting 
activation of IFN-γ production and cytotoxic event.  
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5.7 Overall significance and future directions. 
 The studies discussed in this thesis demonstrate the 
generation of T cells specific for T cell expressed antigens 
to not only be possible, but feasible. The generation of T 
cells capable of targeting T cell expressed antigens has 
implications as a direct cancer immunotherapy for tumor 
targeting as this thesis demonstrates. Beyond a cancer 
immunotherapy, T cell antigen specific T cells could be 
applied for transplant manipulation, for the ablation of 
immune cells as an alternative to chemotherapy or for 
targeting autoimmune diseases such as rheumatoid arthritis. We 
do hypothesize that the generation of such T cells may be 
limited by the CAR to antigen ratio on the T cells. Future 
studies are necessary to better evaluate this possible 
limitation.  
 Although the studies in this thesis do not directly 
evaluate CD56 signaling in T cells, our studies do raise the 
possibility of a role for CD56 signaling in T cells. Minimal 
studies investigate the role of the CD56 antigen on T cells 
and studies looking at the signaling capacity of CD56 in T 
cells are limited. The CD56 antigen expression on T cells 
increases with age and is hypothesized to play a role in 
compensating for the limited T cell pool as you age. A deeper 
understanding of the signaling downstream of CD56 activation 
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in T cells could impact the field of immunology as a whole and 
contribute to understanding the role of the CD56 antigen on T 
cells.  
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CHAPTER 6: Materials & Methods 
6.1 Plasmids 
 The CD19-specific CAR transposon is 
CD19RCD28(CoOp)/pSBSO, which is previously described [11,97]. 
The scFv for the CD56-specific CAR transposon, designated 
CD56RCD28(CoOp)/pSBSO, was generated based upon the CD56 mAb 
clone N901 already used in the clinic [98] and was cloned into 
the CD19RCD28(CoOp)/pSBSO backbone. In short the N901 scFv is 
fused to an IgG4 Fc stalk linked to the CD28 transmembrane and 
CD28 and CD3ζ intracellular domain (Figure 27). The 
∆CD56(CoOp)/pSBSO transposon (Figure 27) contains a codon 
optimized (GENEART) truncated, after the transmembrane domain, 
version of the cell surface antigen CD56 and was cloned into 
the CD19RCD28(CoOp)/pSBSO backbone. The ∆CD19(CoOp)-F2A-
HyTK/pSBSO is previously described [99]. The transposase pKan-
CMV-SB11 is previously described [11,100].  
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Figure 27: Schematic of expression plasmids.  
Transposons: codon optimized delta CD56 and CD56RCD28 second 
generation CAR were cloned under the constitutive hEF-1a 
promoter; IR-SB-inverted/direct repeats; bGhpAn, 
polyadenylation signal from bovine growth hormone; Kanr, 
kanamycin resistance gene. 
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6.2 Cell Lines 
 Neuroblastoma cell lines SK-N-SH, SK-N-BE(2) and IMR-32, 
the astrocytoma/glioma cell line U87, the pre B cell line 
Nalm-6, the small cell lung carcinoma HTB-119 and the 
erythroleukemia cell line K562 Parental were purchased from 
ATCC (American Type Culture Collection, Manassas, VA). The 
cell line CHLA-255 Ffluc is a genetically modified 
neuroblastoma that expresses firefly luciferase (Ffluc) for 
bioluminescent imaging (BLI) and was a kind gift from Dr. 
Seeger (where). EL-4 are from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMA, Braunschwerg, Germany) 
and CD19+ EL-4 were generated as previously described [101]. 
K562 Parental were genetically modified to express a truncated 
form of CD56 by electroporating the ∆CD56(CoOp)/pSBSO 
transposon and SB11 transposase into these cells using Kit V 
nucleofector kit (cat. # VGA-1003, Lonza, Basel, Switzerland) 
and program T16. These electroporated cells were cloned using 
flow activated cell sorting (FACS, UTMDACC core) to generate 
K562 clone #8, which has homogenous CD56 expression. In the 
same manner as just described for the generation of CD56+ K562 
parental (clone 8), truncated CD56 was expressed on K562 clone 
#4, a previously described K562-derived artificial antigen 
presenting cell (aAPC) genetically modified to express CD19, 
CD64, CD86, CD137L and eGFP linked membrane bound IL-15 [97]. 
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A clone was generated through FACS resulting in the generation 
of a CD56+ clone #4, designated clone #11, to be used for the 
expansion of CD56-specific CAR+ T cells (Figure 28). Adherent 
cell lines were cultured in Eagles Minimum Essential Media 
(EMEM) supplemented with 10% heat inactivated fetal bovine 
serum (FBS, Hyclone, Logan UT) and 1% glutamax-100 (Gibco, 
Grand Island, NY) and suspension cell lines were cultured in 
RPMI supplemented with 10% FBS and 1% glutamax-100. All cell 
lines were cultured at 37˚C with 5% CO2 under humidified 
conditions. All cell lines were confirmed by STR DNA 
fingerprinting at the MDACC’s Cancer Center Support Grant 
(CCGS) Core Facility.  
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Figure 28: Phenotype of aAPC clone #11. 
Surface expression of CD56, CD64, CD86, CD137L and eGFP linked 
membrane bound IL-15 as assessed by flow cytometry analysis.    
  
 152 
 
6.3 Generation and propagation of CAR+ T cells 
 A SB transposition on PBMC using the either the 
transposon CD19RCD28(CoOp)/pSBSO or the transposon 
CD56RCD28(CoOp)/pSBSO and transposase SB11(CoOp)/pSBSO was 
performed as previously described [97] using the Human T Cell 
Nucleofector Kit (Lonza, Basel, Switzerland, VAPA-1002) 
according to the manufacturer’s instructions with the 
Nucleofector 2b Device. Electroporated PBMC were stimulated 
and propagated once weekly with γ-irradiated clone 4 or clone 
11 (for CD19CAR and CD56CAR respectively) at a 1:2 ratio of 
CAR+ T cells to aAPC [97]. The exogenous recombinant human 
cytokines IL-21 (30ng/mL beginning 24 hours post-
electroporation, eBioScience, San Diego, CA) and IL-2 (50u/mL 
beginning day 7 post-electroporation, Novartis, Basel, 
Switzerland) were added three times a week on a Mon-Wed-Fri 
schedule over a 28 day culture period. 
6.4 Generation and propagation of autologous targets 
 To expand NK cells un-manipulated PBMC (no transposition 
of genes) were co-cultured with K562 clone 4 at a 1:2 ratio of 
lymphocytes to aAPCs in the presence of IL-2 (30ng/mL) and IL-
21(30ng/mL). Clone 4 were added once every seven days for two 
weeks and at fourteen days of co-culture the cells went 
through a magnetic bead sort for CD3 in order to remove any 
remaining CD3+ T cells in the culture. Only the CD3 negative 
 153 
 
fraction of cells was kept. To generate un-manipulated CD56+ T 
cells, mock transfected PBMC were co-cultured with OKT3 loaded 
K562 clone 4 at a 1:1 ratio of T cells to aAPC in the presence 
of IL-2 (30ng/mL) and IL-21(30ng/mL). This non-specifically 
expands CD3+ T cells though crosslinking of the TCR and results 
in a mixture of CD56neg/+ T cells. Magnetic bead sorting for 
CD56 was performed to separate the CD56neg and CD56+ fractions 
for use in the CRAs.  
 To generate tCD19+ targets the ∆CD19(CoOp)-F2A-HyTK/pSBSO 
transposon was either transfected (1) alone into PBMCs or (2) 
in combination with the CD19RCD28(CoOp)/pSBSO transposon or 
the CD56RCD28(CoOp)/pSBSO transposon using the transposase 
pKan-CMV-SB11 for integration. This resulted in tCD19+ T cells 
(expanded 1:1 with OKT3 loaded clone #4), tCD19+CD19CAR+ T 
cells (expanded 1:2 with clone #4) and tCD19+CD56CAR+ T cells 
(expanded 1:2 with clone #11) respectively. These T cells were 
propagated identically to CAR+ T cells except for the addition 
of hygromycin-B (InvivoGen, CA, cat# ant-hg) at 200mg/mL in 
addition to IL-2 and IL-21 three times a week on a Mon-Wed-Fri 
schedule over a 28 day culture period.  
6.5 Flow Cytometry 
 Cell phenotyping was performed as previously described 
[101]. In short cells were incubated in FACs buffer containing 
Ab dilutions for 30 minutes at 4˚C and washed with FACs buffer 
 154 
 
between stains. Isotype controls were used. The following 
antibodies were used and were purchased from BD Biosciences 
(San Jose, CA) unless otherwise stated: CD3-FITC (cat. 
#349201), CD4-APC (cat. #555349), CD8-PerCPcy5.5 (cat. 
#341051), CD56-APC (cat. #555518), CD19-PerCPCy5.5 (cat. 
#340951), CD28-PerCPcy5.5 (cat. #337181), CD28-PE (cat. 
#555729), CD56-APC (clone B159, cat. #555518), CD56-APC (clone 
16.2, cat. #341025), CD56-APC (Clone N901, Beckman Coulter, 
BC, cat. #IM2474U), CD95-PE (cat. #555674), CD62L-APC (cat. 
#559772), CD32-APC (cat. #559769), CD137L-PE (cat. #559446), 
CD64-PE (cat. #558592), CD86-PE (cat. #555658), TCRvα24-PE 
(Beckman Coulter, BC, cat. #IM228), TCRαβ-FITC (cat. #347773), 
CXCR4-PE (cat. #555974), NKG2D-APC (cat. #558071), PD1-APC 
(cat. #558694), PDL1-PE (cat. #557924), Granzyme B-FITC (cat. 
#560211), Perforin-PE (cat. #556437), Fc-PE (Life 
Technologies, cat. #H10104), CD107a-FITC (cat. #555800)and 
CD69-FITC (cat.#555530). Samples were acquired on FACSCaliber 
(BD Biosciences) and analysis performed using FlowJo software 
(version 7.6.3; TreesStar, Ashland, OR).  
6.6 Chromium Release Assay 
 In vitro four hour chromium release assays (CRA) were 
performed as previously described to assess the cytotoxic 
capacity of CD56-specific CAR+ T cells against CD56+ tumor cell 
lines [11].  CD56 negative cell lines were used as controls to 
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depict background lysis. CRA in the presence of blocking 
antibodies were performed by incubating target cells 1ug/well 
of purified antibody diluted in media for 1 hour at 37˚C and 
then incubating with effectors at a 2:1 effector to target 
ratio for four hours. Media alone was the control for killing 
and CD56 mAb clone 16.2 (BD, cat. # 559043) was used as the 
experimental blocking antibody.  
6.7 Intracellular Cytokine Production 
 In vitro cytokine production by CD56-specific CAR+ T cells 
in response to CD56+ or CD56neg tumor targets was performed as 
previously described [97] using LAC (BD, cat. #550583) for 
non-specific activation control. The following antibodies were 
used for flow cytometry analysis and are from BD Biosciences 
unless otherwise stated: IL10-PE (cat. #554498), IL2-FITC 
(cat. #554565), IL4-APC (cat. #554486), IFNγ-APC (cat. 
#554702), TNFα-PE (cat. #559321), and TGFβ1-APC (R&D Systems, 
cat. #FAB2463A). Intracellular cytokine production in the 
presence of blocking antibodies were performed by incubating 
target cells with 1ug/well of purified antibody diluted in 
media for 30 minutes at 4˚C and then incubated with the 
targets. Media alone was the control for baseline cytokine 
production while CD56 mAb clone N901 (BC, cat. #6602705) was 
used as the experimental blocking antibody. 
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6.8 Cytokine Secretion 
In vitro cytokine secretion studies using the Bio-Rad 27 
Bio-Plex Kit (cat. # 171A11127) were performed as previously 
described [101]. Supernatants were harvested at 24 hours and 
diluted 2 times in media for analysis.  
6.9 Magnetic Bead Sorting 
 Lymphocytes were sorted by magnetic bead sorting using 
the Manual MACS Cell Separation with MACS Microbeads 
(Militenyi Biotec, San Diego, Ca). CD3 negative selection was 
performed on NK cell cultures using human CD3 microbeads 
(Militenyi Biotec, Cat. # 130-050-101) according to the 
manufacturer’s instructions. CD56 negative and positive 
selections were performed using anti-APC microbeads (Militenyi 
Biotec, Cat. # 130-090-855) according to the manufacturer’s 
instructions. The primary staining for the CD56 antigen was 
performed with CD56 (clone B159)-APC (BD, cat. # 555518)using 
5uL/1x10^6 cells. The only modification to the manufacturer’s 
instructions was the negative fraction was not retrieved 
through plunging but through gravity filtration.   
6.10 PKH Staining 
 In order to distinguish between the targets and effectors 
in autologous intracellular cytokine production assays the 
membrane of the effector T lymphocytes were labeled. Using the 
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PKH26 Red Fluorescent Cell Linker Kit for General Cell 
Membrane Labeling (SIGMA ALDRICH, St. Louis, MO, cat. 
#PKH26GL)5x10^6 CAR+ T cells (CD19CAR+ and CD56CAR+) were 
labeled according to the manufacturer’s instructions. In 
short, 1uL PKH26 was diluted in 500uL Diluent C and mixed with 
5x10^6 cells suspended in 500uL Diluent C and incubated at 
room temperature for 5 minutes followed by a minute incubation 
with FBS to inactivate the dye and complete media washes.  
6.11 Mouse Studies 
 The in vivo anti-tumor capacity of CD56-specific CAR+ T 
cells was assessed in NSG mice (NOD.Cg-PrkdcScidIl2rγtm1wjl/SzJ; 
Jackson Laboratories, Bar Harbor, ME) bearing systemic 
neuroblastoma. For the “high” tumor burden study ten NSG mice 
were intravenously injected with 1e6 CHLA-255 Ffluc cells at 
day 0. Through random sorting, these mice were broken into two 
groups (n=5 per group) designated tumor only and T-cell 
treated. Five NSG mice did not receive tumor and were used as 
the T-cell only control. Non-invasive bioluminescent imaging 
was performed following subcutaneous D-Luciferin (Caliper) 
administration to determine tumor burden throughout the study. 
Mice were imaged on the IVIS-100 Imager (Caliper, Hopkinton, 
MA).  21 days post-tumor injection, 107 CD56CAR+ T cells per 
mouse were administered to the T-cell only and T-cell treated 
groups of mice, but not the tumor only group. T-cell infusions 
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were immediately followed by one intraperitoneal IL-2 
injection (60,000 IU/mouse) the day of infusion and twice the 
day after infusion, totaling three IL-2 injections. T-cell 
treatments were repeated once every 7 days for a total of 
three infusions over the course of the study. The “low” tumor 
burden study was identical to the “high” tumor burden study 
except with an n=9 for each the tumor only and T-cell treated 
groups and with T cells being administered once every 7 days 
beginning at day 2 post tumor infusion for a total of three 
infusions. Living Image software (version 2.50, Xenogen, 
Caliper) was used to analyze bioluminescent imaging data. Mice 
were followed for survival which was analyzed using the log-
rank (Mantel-Cox) test. 
6.12 Polysialic Acid Removal (Endoneuraminidase-N Treatment) 
CD56+ K562 Parentals and CHLA-255 were counted and 5x10^6 
cells were incubated with endoneuraminidase-N (Endo-N, ABC 
Scientific, Burbank, CA, cat. #ABC-abc0020) in complete media 
according to manufacturer instructions at 37˚C with 5% CO2 
under humidified conditions. Cells were washed in complete 
media after the four hour incubation and stained for flow 
cytometry analysis.  
 
 
 159 
 
6.13 N-linked Glycosylation Mutants 
Using the CoOp∆CD56/pSBSO transposon as a template each N-
linked glycosylation site was individually mutated. The 
asparganines corresponding to N1-N6 are Asn222, Asn315, 
Asn347, Asn423, Asn449 & Asn478 accordingly and these sites 
were mutated from aparganine to glutamine (n to Q or AAC to 
CAG) REF. Mutants N1-N6 were ordered from GENEART and cloned 
into the CoOp∆CD56/pSBSO backbone. The resulting clones were 
sequenced by the Sequencing & Microarray Facility Department 
of Genetics at MDACC to confirm the presence of the N to Q 
mutation at the proper locations using the following primers: 
M1F (5’-CGTGCGGTTCATCGTGCTGTCCA-3’), M1R (5’-
CACACTTCTTCGCCCACAGCCCTC-3’), M2F (5’-
GAAGAGCATCCAGTACACCGACGCC-3’) and M2R (5’- 
GGCGTCGGTGTACTGGATGCTCTTC-3’). 
6.14 Sequencing of CD56 mRNA 
RNA was extracted from 10^7 CD19CAR+ T cells and CD56CAR+ 
T cells using RNeasy Mini Kit (QIAGEN, cat # 74104). Using the 
SuperScript III First Strand Synthesis System for RT-PCR 
(Invitrogen, cat# 18080-051) We generated cDNA from the 
isolated RNA using gene specific primers [76] CD56-forward 
(5’-ATGCTGCAAACTAAGGATCTCA-3’), CD56-reverse1 (5’-
CTAACAGAGCAAAAGAAGAGTC-3’), CD56-reverse2 (5’-
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TCATGCTTTGCTCTCGTTCTCC-3’). The resulting cDNA was run on 
agarose gel and the bands isolated using the QIAEX II Gel 
Extraction Kit (QIAGEN, cat# 20021). 
After cDNAs were synthesized, sequencing libraries were 
prepared using Nextera® XT DNA Sample Preparation Kit 
(Illumina, San Diego, Cat # FC-131-1024). Following library 
preparation, limited-cycle PCR was performed using primers 
from the Nextera® XT Index Kit (Illumina, San Diego, Cat # FC-
131-1001) to add multiplexing barcodes to the ends of cDNA 
fragments. To ensure high quality reads, the sequencing 
libraries were pooled and purified using Agencourt AmPure XP 
beads (Beckman Coulter, Cat # A63880) and their purity 
measured by spectrophotometry on NanoDrop Lite  (Thermo 
Scientific). 600 µl of denatured DNA at 20 pM spiked with 5% 
PhiX control (Illumina, Cat # FC-110-3001) was loaded onto the 
MiSeq® reagent cartridge (Illumina, MiSeq® Reagent Kit v2 (500 
cycle), Cat # MS-102-2003) for sequencing. 201 x 2 cycles of 
paired-end sequencing reads were demultiplexed and batch 
processed into FASTQ files (Table 5). 
 The sequencing reads were assembled to human CD56 RefSeq 
sequences (NM_000615, NM_001076682, NM_001242607, 
NM_001242608, NM_181351) using Geneious Pro sequence analysis 
software (Biomatters). Consensus sequences were derived from 
best matching contigs. 
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 Two consensus sequences, termed R1 and R2, 
corresponding to the 120 kDa and 140/180 kDa isoforms of CD56 
were identified (reference Appendix A-D for sequence listings, 
including translated (i.e. amino acid) sequence). 
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cDNA Library FASTQ reads % of total reads 
CD19CAR R1 3,709,007 18.3 
CD19CAR R2 4,637,104 22.8 
CD56CAR R1 5,036,715 24.8 
CD56CAR R2 5,769,855 28.4 
PhiX control 1,143,691 5.6 
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Table 5: Quantifying pair-end sequencing reads. 
Demultiplexed and batch processed paired-end sequencing 
reads and the corresponding number of resulting FASTQ files 
(equivalent to reads) and the percent of the total reads each 
library covered. Performed by Dr. Sonny Ang. 
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6.15 Reverse Phase Proteomic Array  
 10^7 CAR+ (CD19CAR+ and CD56CAR+) T cells were pelleted 
and given to MDACC’s CCGS Reverse Phase Proteomic Array (RPPA) 
Core Facility where they were lysed and processed. Data 
analysis was also performed by the RPPA Core Facility. Details 
of the methodology can be found at 
http://www.mdanderson.org/education-and-research/resources-
for-professionals/scientific-resources/core-facilities-and-
services/functional-proteomics-rppa-core/education-and-
references/index.html. RPPA gene products were hierarchically 
clustered and queried using WikiPathways database 
(http://www.wikipathways.org, Kelder T, van Iersel MP, 
Hanspers K, Kutmon M, Conklin BR, Evelo C, Pico AR. (2011) 
WikiPathways: building research communities on biological 
pathways. NAR doi: 10.1093/nar/gkr1074). Resultant pathways 
were parsed, linked, and integrated into a table of shared 
interactions. 
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APPENDIX 
APPENDIX A- R1 consensus sequence 
ATGCTGCAAACTAAGGATCTCATCTGGACTTTGTTTTTCCTGGGAACTGCAGTTTCTCTGCAGGTGGATAT
TGTTCCCAGCCAGGGGGAGATCAGCGTTGGAGAGTCCAAATTCTTCTTATGCCAAGTGGCAGGAGATGCCA
AAGATAAAGACATCTCCTGGTTCTCCCCCAATGGAGAAAAGCTCACCCCAAACCAGCAGCGGATCTCAGTG
GTGTGGAATGATGATTCCTCCTCCACCCTCACCATCTATAACGCCAACATCGACGACGCCGGCATTTACAA
GTGTGTGGTTACAGGCGAGGATGGCAGTGAGTCAGAGGCCACCGTCAACGTGAAGATCTTTCAGAAGCTCA
TGTTCAAGAATGCGCCAACCCCACAGGAGTTCCGGGAGGGGGAAGATGCCGTGATTGTGTGTGATGTGGTC
AGCTCCCTCCCACCAACCATCATCTGGAAACACAAAGGCCGAGATGTCATCCTGAAAAAAGATGTCCGATT
CATAGTCCTGTCCAACAACTACCTGCAGATCCGGGGCATCAAGAAAACAGATGAGGGCACTTATCGCTGTG
AGGGCAGAATCCTGGCACGGGGGGAGATCAACTTCAAGGACATTCAGGTCATTGTGAATGTGCCACCTACC
ATCCAGGCCAGGCAGAATATTGTGAATGCCACCGCCAACCTCGGCCAGTCCGTCACCCTGGTGTGCGATGC
CGAAGGCTTCCCAGAGCCCACCATGAGCTGGACAAAGGATGGGGAACAGATAGAGCAAGAGGAAGACGATG
AGAAGTACATCTTCAGCGACGATAGTTCCCAGCTGACCATCAAAAAGGTGGATAAGAACGACGAGGCTGAG
TACATCTGCATTGCTGAGAACAAGGCTGGCGAGCAGGATGCGACCATCCACCTCAAAGTCTTTGCAAAACC
CAAAATCACATATGTAGAGAACCAGACTGCCATGGAATTAGAGGAGCAGGTCACTCTTACCTGTGAAGCCT
CCGGAGACCCCATTCCCTCCATCACCTGGAGGACTTCTACCCGGAACATCAGCAGCGAAGAAAAGACTCTG
GATGGGCACATGGTGGTGCGTAGCCATGCCCGTGTGTCGTCGCTGACCCTGAAGAGCATCCAGTACACTGA
TGCCGGAGAGTACATCTGCACCGCCAGCAACACCATCGGCCAGGACTCCCAGTCCATGTACCTTGAAGTGC
AATATGCCCCAAAGCTACAGGGCCCTGTGGCTGTGTACACTTGGGAGGGGAACCAGGTGAACATCACCTGC
GAGGTATTTGCCTATCCCAGTGCCACGATCTCATGGTTTCGGGATGGCCAGCTGCTGCCAAGCTCCAATTA
CAGCAATATCAAGATCTACAACACCCCCTCTGCCAGCTATCTGGAGGTGACCCCAGACTCTGAGAATGATT
TTGGGAACTACAACTGTACTGCAGTGAACCGCATTGGGCAGGAGTCCTTGGAATTCATCCTTGTTCAAGCA
GACACCCCCTCTTCACCATCCATCGACCAGGTGGAGCCATACTCCAGCACAGCCCAGGTGCAGTTTGATGA
ACCAGAGGCCACAGGTGGGGTGCCCATCCTCAAATACAAAGCTGAGTGGAGAGCAGTTGGTGAAGAAGTAT
GGCATTCCAAGTGGTATGATGCCAAGGAAGCCAGCATGGAGGGCATCGTCACCATCGTGGGCCTGAAGCCC
GAAACAACGTACGCCGTAAGGCTGGCGGCGCTCAATGGCAAAGGGCTGGGTGAGATCAGCGCGGCCTCCGA
GTTCAAGACGCAGCCAGTCCGGGAACCCAGTGCACCTAAGCTCGAAGGGCAGATGGGAGAGGATGGAAACT
CTATTAAAGTGAACCTGATCAAGCAGGATGACGGCGGCTCCCCCATCAGACACTATCTGGTCAGGTACCGA
GCGCTCTCCTCCGAGTGGAAACCAGAGATCAGGCTCCCGTCTGGCAGTGACCACGTCATGCTGAAGTCCCT
GGACTGGAATGCTGAGTATGAGGTCTACGTGGTGGCTGAGAACCAGCAAGGAAAATCCAAGGCGGCTCATT
TTGTGTTCAGGACCTCGGCCCAGCCCACAGCCATCCCAGCAACCTTGGGAGGCAATTCTGCATCCTACACC
TTTGTCTCATTGCTTTTCTCTGCAGTGACTCTTCTTTTGCTCTGTTAG 
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APPENDIX B- R1 consensus sequence translation 
1 mlqtkdliwt lfflgtavsl qvdivpsqge isvgeskffl cqvagdakdk 
diswfspnge 
61 kltpnqqris vvwnddssst ltiynanidd agiykcvvtg edgseseatv 
nvkifqklmf 
121 knaptpqefr egedavivcd vvsslpptii wkhkgrdvil kkdvrfivls 
nnylqirgik 
181 ktdegtyrce grilargein fkdiqvivnv pptiqarqni vnatanlgqs 
vtlvcdaegf 
241 peptmswtkd geqieqeedd ekyifsddss qltikkvdkn deaeyiciae 
nkageqdati 
301 hlkvfakpki tyvenqtame leeqvtltce asgdpipsit wrtstrniss 
eektldghmv 
361 vrsharvssl tlksiqytda geyictasnt igqdsqsmyl evqyapklqg 
pvavytwegn 
421 qvnitcevfa ypsatiswfr dgqllpssny snikiyntps asylevtpds 
endfgnynct 
481 avnrigqesl efilvqadtp sspsidqvep ysstaqvqfd epeatggvpi 
lkykaewrav 
541 geevwhskwy dakeasmegi vtivglkpet tyavrlaaln gkglgeisaa 
sefktqpvre 
601 psapklegqm gedgnsikvn likqddggsp irhylvryra lssewkpeir 
lpsgsdhvml 
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661 ksldwnaeye vyvvaenqqg kskaahfvfr tsaqptaipa tlggnsasyt 
fvsllfsavt 
721 llllc*// 
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APPENDIX C- R2 consensus sequence 
ATGCTGCAAACTAAGGATCTCATCTGGACTTTGTTTTTCCTGGGAACTGCAGTTTCTCTGCAGGTGGATAT
TGTTCCCAGCCAGGGGGAGATCAGCGTTGGAGAGTCCAAATTCTTCTTATGCCAAGTGGCAGGAGATGCCA
AAGATAAAGACATCTCCTGGTTCTCCCCCAATGGAGAAAAGCTCACCCCAAACCAGCAGCGGATCTCAGTG
GTGTGGAATGATGATTCCTCCTCCACCCTCACCATCTATAACGCCAACATCGACGACGCCGGCATTTACAA
GTGTGTGGTTACAGGCGAGGATGGCAGTGAGTCAGAGGCCACCGTCAACGTGAAGATCTTTCAGAAGCTCA
TGTTCAAGAATGCGCCAACCCCACAGGAGTTCCGGGAGGGGGAAGATGCCGTGATTGTGTGTGATGTGGTC
AGCTCCCTCCCACCAACCATCATCTGGAAACACAAAGGCCGAGATGTCATCCTGAAAAAAGATGTCCGATT
CATAGTCCTGTCCAACAACTACCTGCAGATCCGGGGCATCAAGAAAACAGATGAGGGCACTTATCGCTGTG
AGGGCAGAATCCTGGCACGGGGGGAGATCAACTTCAAGGACATTCAGGTCATTGTGAATGTGCCACCTACC
ATCCAGGCCAGGCAGAATATTGTGAATGCCACCGCCAACCTCGGCCAGTCCGTCACCCTGGTGTGCGATGC
CGAAGGCTTCCCAGAGCCCACCATGAGCTGGACAAAGGATGGGGAACAGATAGAGCAAGAGGAAGACGATG
AGAAGTACATCTTCAGCGACGATAGTTCCCAGCTGACCATCAAAAAGGTGGATAAGAACGACGAGGCTGAG
TACATCTGCATTGCTGAGAACAAGGCTGGCGAGCAGGATGCGACCATCCACCTCAAAGTCTTTGCAAAACC
CAAAATCACATATGTAGAGAACCAGACTGCCATGGAATTAGAGGAGCAGGTCACTCTTACCTGTGAAGCCT
CCGGAGACCCCATTCCCTCCATCACCTGGAGGACTTCTACCCGGAACATCAGCAGCGAAGAAAAGGCTTCG
TGGACTCGACCAGAGAAGCAAGAGGTACATGCACCATGGAACTGGCAAGTGGGCAGACAGAAAGGACAGGC
TGGCAGTGCAGGTTTCCCAGGATCTCATGAGACTCTGGATGGGCACATGGTGGTGCGTAGCCATGCCCGTG
TGTCGTCGCTGACCCTGAAGAGCATCCAGTACACTGATGCCGGAGAGTACATCTGCACCGCCAGCAACACC
ATCGGCCAGGACTCCCAGTCCATGTACCTTGAAGTGCAATATGCCCCAAAGCTACAGGGCCCTGTGGCTGT
GTACACTTGGGAGGGGAACCAGGTGAACATCACCTGCGAGGTATTTGCCTATCCCAGTGCCACGATCTCAT
GGTTTCGGGATGGCCAGCTGCTGCCAAGCTCCAATTACAGCAATATCAAGATCTACAACACCCCCTCTGCC
AGCTATCTGGAGGTGACCCCAGACTCTGAGAATGATTTTGGGAACTACAACTGTACTGCAGTGAACCGCAT
TGGGCAGGAGTCCTTGGAATTCATCCTTGTTCAAGCAGACACCCCCTCTTCACCATCCATCGACCAGGTGG
AGCCATACTCCAGCACAGCCCAGGTGCAGTTTGATGAACCAGAGGCCACAGGTGGGGTGCCCATCCTCAAA
TACAAAGCTGAGTGGAGAGCAGTTGGTGAAGAAGTATGGCATTCCAAGTGGTATGATGCCAAGGAAGCCAG
CATGGAGGGCATCGTCACCATCGTGGGCCTGAAGCCCGAAACAACGTACGCCGTAAGGCTGGCGGCGCTCA
ATGGCAAAGGGCTGGGTGAGATCAGCGCGGCCTCCGAGTTCAAGACGCAGCCAGTCCGGGAACCCAGTGCA
CCTAAGCTCGAAGGGCAGATGGGAGAGGATGGAAACTCTATTAAAGTGAACCTGATCAAGCAGGATGACGG
CGGCTCCCCCATCAGACACTATCTGGTCAGGTACCGAGCGCTCTCCTCCGAGTGGAAACCAGAGATCAGGC
TCCCGTCTGGCAGTGACCACGTCATGCTGAAGTCCCTGGACTGGAATGCTGAGTATGAGGTCTACGTGGTG
GCTGAGAACCAGCAAGGAAAATCCAAGGCGGCTCATTTTGTGTTCAGGACCTCGGCCCAGCCCACAGCCAT
CCCAGCCAACGGCAGCCCCACCTCAGGCCTGAGCACCGGGGCCATCGTGGGCATCCTCATCGTCATCTTCG
TCCTGCTCCTGGTGGTTGTGGACATCACCTGCTACTTCCTGAACAAGTGTGGCCTGTTCATGTGCATTGCG
GTCAACCTGTGTGGAAAAGCCGGGCCCGGGGCCAAGGGCAAGGACATGGAGGAGGGCAAGGCCGCCTTCTC
GAAAGATGAGTCCAAGGAGCCCATCGTGGAGGTTCGAACGGAGGAGGAGAGGACCCCAAACCATGATGGAG
GGAAACACACAGAGCCCAACGAGACCACGCCACTGACGGAGCCCGAGAAGGGCCCCGTAGAAGCAAAGCCA
GAGTGCCAGGAGACAGAAACGAAGCCAGCGCCAGCCGAAGTCAAGACGGTCCCCAATGACGCCACACAGAC
AAAGGAGAACGAGAGCAAAGCATGA 
  
 169 
 
APPENDIX D- R2 consensus sequence translation 
1 mlqtkdliwt lfflgtavsl qvdivpsqge isvgeskffl cqvagdakdk 
diswfspnge 
61 kltpnqqris vvwnddssst ltiynanidd agiykcvvtg edgseseatv 
nvkifqklmf 
121 knaptpqefr egedavivcd vvsslpptii wkhkgrdvil kkdvrfivls 
nnylqirgik 
181 ktdegtyrce grilargein fkdiqvivnv pptiqarqni vnatanlgqs 
vtlvcdaegf 
241 peptmswtkd geqieqeedd ekyifsddss qltikkvdkn deaeyiciae 
nkageqdati 
301 hlkvfakpki tyvenqtame leeqvtltce asgdpipsit wrtstrniss 
eekaswtrpe 
361 kqevhapwnw qvgrqkgqag sagfpgshet ldghmvvrsh arvssltlks 
iqytdageyi 
421 ctasntigqd sqsmylevqy apklqgpvav ytwegnqvni tcevfaypsa 
tiswfrdgql 
481 lpssnysnik iyntpsasyl evtpdsendf gnynctavnr igqeslefil 
vqadtpssps 
541 idqvepysst aqvqfdepea tggvpilkyk aewravgeev whskwydake 
asmegivtiv 
601 glkpettyav rlaalngkgl geisaasefk tqpvrepsap klegqmgedg 
nsikvnlikq 
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661 ddggspirhy lvryralsse wkpeirlpsg sdhvmlksld wnaeyevyvv 
aenqqgkska 
721 ahfvfrtsaq ptaipangsp tsglstgaiv gilivifvll lvvvditcyf 
lnkcglfmci 
781 avnlcgkagp gakgkdmeeg kaafskdesk epivevrtee ertpnhdggk 
htepnettpl 
841 tepekgpvea kpecqetetk papaevktvp ndatqtkene ska*// 
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APPENDIX E- CD19CAR Normal Log2 median centered values for 
hierarchical clustering
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APPENDIX F- CD56CAR Normal Log2 median centered values for 
hierarchical clustering  
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